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Systems Biology Approaches to Precision Medicine
Jing He
This dissertation describes the development and implementation of two systems biology methods:
ADVOCATE and hpARACNE.
ADVOCATE (Adaptive DeconVolution Of CAncer Tissue Expression - ADVOCATE) was de-
signed to deconvolve epithelial and stromal compartment fractions, and their corresponding virtual
expression proles, from bulk gene expression proles in patients. To do this, we combined laser
capture microdissection and RNA sequencing to disentangle the transcriptional programs active in
the malignant epithelium and stroma of pancreatic ductal adenocarcinoma (PDA), an aggressive
malignancy with a prominent stromal component. We learned that distinct molecular subtypes are
present in both the epithelium and the stroma of pancreatic cancer, and that the subtype identity
of these two compartments are independent of one another. Critically, we discovered that specic
combinations of epithelial and stromal subtypes are strongly associated with patient survival across
multiple external datasets, exhibiting both an eect-size and a level of reproducibility that was ab-
sent from previous eorts. ADVOCATE accurately predicted the compartment fractions of bulk
tumor samples and improved the performance of molecular classiers by controlling for the diverse
cellular compositions of independent datasets. This approach provides a much needed framework to
handle solid tumor tissue heterogeneity, allowing integrated analysis of both epithelial and stromal
transcriptional programs from individual bulk samples.
hpARACNE (hybrid proteomicsAlgorithm for theReconstruction of AccurateCellularNetwork),
is a re-design of gene expression based ARACNE algorithm. Reverse engineering approaches, such
as ARACNE, use gene expression proles to systematically dissect regulatory interactions in dier-
ent contexts, thus improving our understanding of the regulation of transcriptional programs and
through them, the broader state of the cell. Proteomics data, on the other hand, provides direct
evidence of the instantaneous state of cellular signaling networks. Often, such signaling molecules
are the best candidates for drug targets, and drugs that specically aect key signaling proteins
have been eective in treating some types of cancer. Using Clinical Proteomics Tumor Analysis
Consortium (CPTAC) breast cancer proteomics data, hpARACNE reconstructs a network that
signicantly outperforms ARACNE when compared with curated signaling network. Compared
with Stable Isotope Labeling with Amino acid in Cell Culture (SILAC) experimentally identied
substrates for EGFR, hpARACNE predicts substrates with high accuracy. Applying this signal-
ing network, together with transcriptional network from the same samples, reveals potential drug
targets for Triple Negative Breast Cancer (TNBC) treatment. hpARACNE has three innovations
that adapt it to proteomics data and signaling process: 1) Renement of the kinase/phosphatase
peptides by integrating matched whole proteomic and whole phosphoproteomic proles; 2) Estab-
lishment of association based on newly designed Mutual Information (MI) estimator for missing
data; 3) Network pruning using directional Data Processing Inequality (dDPI) for signaling pro-
cess.
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21.1 Introduction to systems biology
A collection of reviews inspired the composition of this section, including [Westerho and Palsson,
2004] regarding molecular biology development, systems theories summary from [Kesic, 2016], and
the prospect of systems biology by [Vidal, 2009]. Systems biology studies biological systems using
computational and mathematical modeling tools, focusing on the structure of interactions and the
eects on biological function and system behavior.
1.1.1 A brief history of systems biology
As implicated by its name, systems biology has historical roots in both systems theory and molecu-
lar biology. These two roots only converge until recently to form this \new" eld of systems biology
[Westerho and Palsson, 2004]. In general, the contemporary systems biology developed in three
phases (Figure 1.1). During the rst phase, molecular biologists experimented on individual com-
ponent of a system, the classical \reductionist" perspective. On the theory side, Newton's success
in explaining physical properties one-by-one reinforced by reductionist thinking in systems theory
eld. However, several experimental attempts from both bio-chemical and phenotypic perspectives
brought systems thinking into bio-medical researches. For example, [Michaelis and Menten, 1913]
introduced regulation and interaction, a new concept back then, by showing its eectiveness in ex-
plaining the mechanism of enzymes controlling chemical processes in metabolic pathways. [Weiss,
1925] rst observed that light and gravity jointly triggered animals reactions, which rst formulated
the theoretical assumptions of behaviorism systematically.
Case-by-case knowledge transfer of systems theories from physics to biology signied the second
developmental phase of systems biology, with an acceleration from 1950s to 1960s. This transmis-
sion arose at dierent scales: single molecules characterization, molecule interaction demonstration,
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Figure 1.1: The brief time of Systems Biology
tematic characterization of molecules, i.e. metabolites. [Gerhart and Pardee, 1962] then discovered
interactions - the feedback inhibition - of amino acid biosynthetic pathways, a complicated com-
petitive interactions circuit among enzymes. Another bedrock study by [Keys, 1957] demonstrated
individual heterogeneity, a type of systems perturbations, by innumerable anatomical and physio-
logical examples, thus revolutionizing the whole biomedical research eld. Expanding subsequent
experiments demonstrated that interactions, linear or nonlinear, was an essential and necessary
property of biological systems. [Jacob and Monod, 1961] exemplied these eorts by discovering
the Trp operon, a repressive regulatory circuit, in Escherichia coli (E.coli) with its ve member
genes collectively being inhibited by the chemical trytophan, thus precluding the elucidation of
complex regulatory mechanisms. [Beckwith, 1967] next clearly explained the genetic mechanism
of lac operon, a three-gene set that was controlled by both regulatory substance (lactose family)
and DNA sites(promoter gene) in E.coli. Not only experimental evidence was accumulating, but
also systematic theories were formalized and popularized, i.e. general systems theories [Mesarovic,
1964], which was preparing systems biology to step into the next developmental phase.
4The third phase witnessed the maturation of systems biology, represented by system-centered
research advancements and large-scale experimental quantitation technology developments around
1980s  1990s. Before the era of high-throughput data generation, most systems biology method-
ologies were based on in silico designs, i.e. simulations. Though they replicated substantial aspects
of the real world, they still failed to capture the complexity of realistic scenarios. High-throughput
experimental data, on the other hand, provided invaluable resources to do systematically mathe-
matical modelling. For example, data from recombinant technology (1970s) powered genetic mate-
rial manipulation helped systematically investigate regulation mechanisms. Automated sequencing
(1980s) and high-throughput genome-scale technologies (1990s) then fastened biological systems
characterizations, such as the completion of E.coli genome DNA sequencing (1997). The avail-
ability of these bacteria molecular data, i.e. E.coli and Saccharomyces (yeast) promoted network
reconstruction and analysis. For example, [Shen-Orr et al., 2002] rst delineated three basic net-
work motifs with their biological functions in E.coli. [Guelzim et al., 2002] then took a dierent
perspective, analyzed yeast regulatory network topology, showing that, instead of randomly con-
nected, the network was organized by hubs and connectors. [Albert and Barabasi, 2002] further
summarized the characteristics and formalized the properties of these biological networks, also
known as scale-free networks. Though still focusing on prokaryotes and model systems, these stud-
ies paved the road for investigating mammalian regulatory circuits. [Goh et al., 2007] then showed
that hubs genes in a human disease network were more likely to be essential genes, whereas disease
genes were less likely to locate at hubs. Further analysis of such context-specic network could
prioritize genes/proteins that were key to specic phenotype, i.e cancer, and thus guide future
clinical practice [Barabasi et al., 2011].
1.1.2 The fth prism
[Vidal, 2009] pointed out that modern biology had four classical mature prisms: biochemistry,
genetics, cell biology and evolutionary biology (Figure 1.2). Contemporary systems biology, aside
from all the others, is the fth prism that connects the four established prisms by systems theory.
Systems biology rst applies systems thinking to each eld to investigate biological arrangements
such as metabolic networks, gene regulations, protein-protein interactions and population struc-
tures. It then links these mono-scale architecture into multi-scale hierarchies to study inter-prism
5associations such as integrative interaction of genetic mutations, mRNAs and functional pathways.
In addition to static network properties such as centrality and modularity, it also inspect network
dynamics such as evolution and oscillation.
Biochemistry Genecs
Cell biology Evoluon
Figure 1.2: The Five prism of biology
Systems biologists assume that no life form can be imagined without complex systems formed
by interacting genes, macro-molecules, or cells [Vidal, 2009]. Based on this hypothesis, systems
biology views biological problems in a global and integrative way: components of biological system
interact with each other to form dynamic and global models. By exploiting large-scale mathematical
models and leveraging computational algorithms, the properties of such models could be investi-
gated to explain biological function system-level interactions. [Bateson, 1981] rst experimentally
demonstrated the intricate relationship between bird development and its environment inuence
- a process known as \imprinting". This work drew attention to not only genetic or molecular
interactions but also internal-external relationships. [Di Lollo et al., 2000] further consolidated
the signicance of systems biology at explaining complex biological relationships. This cornerstone
6work explained excellently that biological systems oscillations: the visual signaling transduction
processes were simultaneously controlled by inhibitory contour intracellular network, instead of
relying on the prevailing feed-forward mechanism only. Thus, network research was believed not
only as an add-on but a necessity to biological researches. Researchers then started to utilize sys-
tems biological theory as a powerful tool to discern generalizable principles underlying biological
systems. [Hoefnagel et al., 2002] quantitatively demonstrated the long-held \bottle-neck" theory
and \rate-limiting" assumption by delineating the metabolic control circuits of cells. [Edwards and
Rohwer, 2005] then over-viewed network topology analysis in viral diversity studies and community
structure discoveries based on large-scale genetic models.
Like connecting dots to outline an object in painting, the case-by-case search for biological
mechanisms or principles precluded the uncovering of global characterization of biological systems
based on interactions. Nowadays, a global regulatory network could be readily reconstructed in
minutes so that researchers interested in any regulatory gene could drill down any regulatory
mechanism. For example, [Basso et al., 2005] rst constructed a regulatory network in human
B-cells, and then used this network and identied MYC as a hub gene in B-cells development.
Likewise, [Carro et al., 2009] reverse engineered human brain regulatory network that facilitated
the subsequent discovery of master regulator genes for mesenchymal transition of human cells.
1.1.3 Cancer systems biology: from a computational perspective
A tumor is a complex system comprised of multiple cell types, both malignant and nonmalignant,
that are in many ways functionally interconnected. Thus, cancer research calls for systems per-
spective that could model the intricate relationship among these cells and approaches that could
pinpoint the key control points for carcinogenesis or tumor progress. From late 20s, by investigating
dierent cancer-system-related questions and studying them using systems biology methodologies,
systems biology started playing a signicant role in cancer research and providing valuable clinical
guidance to cancer treatment.
Systems biology revolutionized molecular biology by utilizing networks to discover mechanisms
of carcinogenesis or cancer progression process. [De Craene and Berx, 2013] reviewed the key
Epithelial to Mesenchymal Transition (EMT) regulatory circuit, a network centered around ZEB,
SNAIL, and TWIST family. Many of such regulatory machinery were experimentally validated,
7i.e. [Min et al., 2012] showed the role of c-Jun regulatory circuit in controlling cell survival dur-
ing liver cancer initiation. The understanding of molecular interactions further promoted tumor
outcome predictions. [Pomeroy et al., 2002], for example, derived a classication system to predict
medulloblastomas -a specic pediatric brain tumor- outcome.
Discoveries in tumor initiation and progression guided clinical practice by providing improve-
ments in treatment outcome prediction and biomarkers for tumor screening. Systems biology is able
to prioritize specic treatment candidates in dierent context by studying the interactions between
chemicals, molecules, tumor and related cells, and even cancer patients. [Pegram and Slamon, 1999]
rst demonstrated that the combination of trastuzumab and cisplatin that targets HER2 and DNA
replication achieved a signicantly higher response rates than that of either single agent treatment
alone. Such receptor-enhanced and chemo-sensitive combinations inspired approaches targeting
over-expressed growth factor receptors in a variety of cancers, leading to de novo molecule-based
therapeutic strategies for clinical interventions.
How these interactions are related to endogenous or exogenous environments is another con-
sequential question, i.e. how dierent treatment targets cooperate or counteract under dierent
perturbations. Addressing this question would help to explore treatment combinations or alter-
natives for cancer patients. [Chou, 2006] pioneered this eld and theorized drug synergy and
resistance models, based on which systematic chemical compounds combination screening were im-
plemented. National Cancer Institute (NCI)-60 cell line drug screening narrowed down candidate
drugs for potential treatments using both experimental [Alley et al., 1988] and computational meth-
ods [Shoemaker, 2006]. The Cancer Cell Line Encyclopedia (CCLE) further examined expression
proles for  1000 cell lines with known genetic background using 24 drugs with pharmacological
proles, thus establishing a preclinical stratication schemata for these agents [Barretina et al.,
2012a].
Next, a natural extending question would be what eect a treatment could cause, i.e. cell
apoptosis/death, known as drug response. Computational methods could be equipped a prior to
promote drugs of high ecacy and avoid those with side-eect. [Kholodenko et al., 1999] success-
fully elucidated Epithelial Growth Factor Receptor (EGFR) signaling cellular response by integrat-
ing experimental kinetic analysis and computational modeling of cellular responses to Epidermal
Growth Factor (EGF) in isolated hepatocytes. [Schoeberl et al., 2002] traced this founding and
8computational modelled its downstream Mitogen-Activated Protein (MAP) kinase cascade and ex-
perimentally validated it. [Park et al., 2003] then assessed the kinetics of Protein Kinase B (PKB,
Akt) pathway, which was shown to be mediated by Platelet-Derived Growth Factor (PDGF), an-
other growth factor that regulates cell growth and division. [Sasagawa et al., 2005] later simulated
the dynamics of extracellular-signal-regulated kinase (ERK) signalling networks, predicted and val-
idated that transient ERK activation depends on rapid increases of EGF and nerve growth factor
(NGF).
Understanding of these pathways assisted extensive large-scale computational modeling and
systematical prediction of candidate synergistic drug pairs which have been shown as eective
treatments for metastasis breast cancer. [Bansal et al., 2014] initiated a community eort and
computationally prioritized 91 compound pairs based on experimental data. This work demon-
strated possibility of computational prediction of compound-pair activity based on gene expression
proles. [Woo et al., 2015] then successfully identicatied Mechanism of Action (MoA) of small
molecule compounds based on interactome, thus providing critical implications for assessment of
compounds ecacy and toxicity. Synthetic lethality, on the other hand, approached combination
therapy through genetics level. Two genes are synthetic lethal if mutation of either alone is compat-
ible with viability but mutation of both leads to death. Thus, targeting synthetic lethal gene-pairs
provides a conceptual framework for the development of cancer-specic cytotoxic agents. [Kaelin,
2005] reviewed systematical identication of synthetic lethal genes. While these studies focused
on single dataset, other studies started to leverage big data resources to integrate information to
predict candidate drug/drug-pair as reviewed by [Chen and Butte, 2016].
1.1.4 High throughput technology
The maturation of high-throughput quantication technology is the prerequisite for systems bi-
ology. Next generation sequencing data provides rich resources to the research community. Or-
ganizational eorts, such as The Cancer Genome Atlas (TCGA), International Cancer Genome
Consortium (ICGC), generated whole genome genetic quantication (DNA-seq) and whole tran-
scriptome proling (RNA-seq), thus nurtured hundreds of published discoveries across all major
cancer types. Proteomics, whereas, used to be a labor-intensive eld with extreme challenges in
protein quantication. Bottom-up shot-gun whole proteomic proling provided a fast and accu-
9rate solution to quantify whole proteome/phosphoproteome. Past decade has witnessed matur-
ing of whole proteome proling using Liquid Chromatography Mass-Spectrometry (MS) coupled
with MS2 (LC-MS/MS) for peptides from either cultured cells or clinical samples [Mann, 2006;
Wiese et al., 2007; Dayon et al., 2008]. Clinical Proteomic Tumor Analysis Consortium (CPTAC)
lead the eort in whole proteome quantication, produced LC-MS/MS based whole proteome and
functional proteomics data of Breast cancer, Colonrectal cancer and Ovarian cancer samples.
However, with accumulated knowledge of cancer biology/treatment, it is only more complicated
that we nd out this malignancy is. Further understanding of the complexity calls for technologies
with ner resolution but lesser noise, higher throughput but lower cost, faster speed but increased
accuracy. Even though we achieved great cost reduction for next generation sequencing, but current
sample preparation protocol failed to capture the heterogeneity resides in each tumor. Thus, high
quality single cell sequencing technologies are in avid needs. However, molecular proling of some
highly inltrated tumors such as Pancreatic Ductal Adenocarcinoma (PDA) is still challenging.
The hurdles of handing sample heterogeneity only become worse in protein level. s of our inability to
amplify proteins, global proteomics quantication remains a demanding eld. When accounting for
the experimental and technique constrains, computational algorithms become indispensable tools




Tumors originated from dierent tissues usually manifest distinct phenotype, morphology, molec-
ular proles or genetic background - a phenomenon known as inter-tumor heterogeneity. Those
dierences are exemplied by the fact dierent cell types are identied in dierent tumors. For
example, liquid tumors such as leukemia are mostly derived from hematopoietic stem cells; while
solid tumors such as breast invasive ductal adenocarcinoma are believed to develop from epithelial
stem cells. Morphalogical staining of dierent tumor tissue, such as breast cancer, liver cancer,
colon cancer and pancreatic cancer, illustrated such intra-tumor histopathological heterogeneity of
tumors (ImagePedia, ImagePedia.com, Figure 1.3). It is clear that tn addition to the founding
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cells, cancers usually include other cell types, including epithelial cells, stromal cells, immune cells,
normal tissue cells, etc.
Tumors originated from one tissue also demonstrate variational composition of cell types - a
phenomenon known as intra-tumor heterogeneity. This intra-tumor heterogeneity has been shown
to fuel up tumor progression as well as treatment resistance. In this context, if not pointed specif-
ically, intra-tumor heterogeneity will be referred as heterogeneity in general. Patients having the
same tumor could manifest distinct phenotypic outcomes that was caused by individual genetic
makeup or imprinted by specic environment. Genetic heterogeneity can arise from mutations,
genomic instability or defects in mitosis. Even for silimar genetic background, tumors could show
transcriptional dierence that is regulated by a set of Master Transcription Factors (TF) (Master
Regulators, MRs). Epigenetic changes could be the driving mechanism for cancer heterogene-
ity. [Feinberg et al., 2006] reviewed the epigenetic progenitor model for cancer, depicting the
role of epigenetic progenitor variation and epigenetic plasticity in driving cancer heterogeneity.
Consistent with this model, [Yegnasubramanian et al., 2008] then detailed the late on-set of DNA
hypomethylation in prostate cancer, with a signicant tendency of only in metastatic stage. [Shack-
leton et al., 2009] later expanded the progenitor model, solidied that both genetic and epigenetic
mechanisms contributed to cancer heterogeneity if intrinsic dierences between tumorigenic and
nontumorigenic cells were to be assumed, either in cancer stem cell model, or clonal evolution
model. [Hansen et al., 2011] demonstrated that stochastic methylation variation of cancer-specic
dierentially DNA-methylated regions that were linked to loss of methylation boundaries at CpG
islands across cancer types. Microenvironment, such as oxygen or nutrition level, could induce such
epigenetic changes which then impose distinct selective pressure on tumor cells progression, thus
causing regional heterogeneity and varying subclone evolution [Orel et al., 2004; Feig et al., 2012a;
Fearon, 2014].
1.2.2 Heterogeneity and therapy
Cancer inltrated stroma is drawing ever-increasing attention in cancer biology. The cornerstone
publication [Dvorak, 1986], Tumors: Wounds that do not heal, compares healthy wound healing and
the stroma maturation process in tumor environments and nds a role of stroma in tumor initiation




Liver Cancer Breast Cacner (NOS)
Figure 1.3: Histopathology images of dierent types of carcinomas (Images were downloaded from ImagePe-
dia.com. A. Large intestinal carcinoid tumors can show morphological ribbon-like growth pattern or with
tubular/acinar or tubuloacinar pattern. The tumor focally extends into the overlying mucosa. All other
gland-like structures and solids nests are carcinoid tumor clusters (curved arrow). B. Pancreatic ductal
adenocarnima. Although most tumors are composed of larger glands, small tubular glands and ductal struc-
tures can also be seen. The presence of nuclear atypia and desmoplasia is a clear-cut feature of the invasive
nature of the lesion. C. Hepatocellular carcinoma (HCC). A solid growth pattern with large tumor nodules
separated by thick brous bands can be seen in moderately to poorly dierentiated HCC.The malignant
nature of such tumor is obvious by the aberrant architecture. D. Invasive ductal breast carcinoma of no
special type is the most common invasive breast malignancy. Depending on the grade the tumor may form
glands and tubules and shows stromal desmoplasia. Well dierentiated tumors show gland/tubule formation
in > 75% of the invasive component and contain round to oval nuclei with few mitoses. Note round to
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TRENDS in Cell Biology 
Figure 1.4: Major constituents of the tumor microenvironment (TME) and TME-targeted therapies. The
TME comprises various cell types that modulate treatment response and are putative candidates for thera-
peutic intervention. [Klemm and Joyce, 2015]
connective tissues and brin-gel, exhibit a phenotype similar to the wounding healing process.
But in contrast to normal tissue, they emphasize the presence of brin regulation with abnormal
brinolysis and brin accumulation in tumor tissue. Following that work, [Mullin, 2004] explains
that normal stroma function as a barrier to isolate growth factors, where the breakdown of stroma
barrier in tumor tissue allows the invasion of growth factors.
Regardless of the causes, it is believed that heterogeneity, in particular within the tumor
microenvironment, might aect tumor treatment [Klemm and Joyce, 2015] through interactions
between types of agents and malignant cells (Figure 1.4). In liver cancers such as hepatocellu-
lar carcinoma (HCC) and intra-hepatic calangiocarcinoma (ICC), [Coulouarn and Clement, 2014]
overviewed the cross-talk between tumor and stromal cells, especially hepatocellular stromal cells
(HSC), is relating to HCC onset and might be potential therapeutic modalities. In particular, cancer
stellate cells aect tumor growth by secreting growth factors, matrix proteases, and ECM proteins.
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(b)
Figure 1.5: Tumor specic microenrionment (a).liver cancers [Coulouarn and Clement, 2014] and (b). pan-
creatic ductal adenocarcinoma. [Feig et al., 2012b]
microenvironment [Wonsey and Follettie, 2005; Heindryckx and Gerwins, 2015]. [Feig et al., 2012b]
reviewed that, in pancreatic cancer (PDA) microenvironment, Pancreatic Stellate Cells (PSC) are
interacting with both PDA cells and endothelial cells, implicating its role of promoting tumor cell
growth. [ Ozdemir et al., 2014], on the contary, showed that depletion of inltrated stroma in PDA
does not bring better survival but worse, precluding the intricate interaction between stroma and
tumor cells residing in the microenvironment. Factors such as interactions with immune systems
should be considered when treating stroma as part of the tumor system [Fearon, 2014].
1.2.3 Technologies to study tumor heterogeneity
Dierent techniques have been used to study tumor heterogeneity. In particular, to understand
intra-tumor transcriptional heterogeneity, i.e. distinct RNA expression proles from the same
tumor type, macro-/micro- dissections are used to layout the landscape of regional/morphological
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heterogeneity through both experimental and computational methodologies. For example, high
resolution microscopes help visualize morphological variability of tumor specimen. Laser Capture
Microdissection (LCM) [Emmert-Buck et al., 1996], coupled with other high-throughput quantation
techniques such as RNA-seq, is used to study molecular characteristics of morphologically distinct
heterogeneity. Single cell RNA-seq proling [Patel et al., 2014], which provides quantication of a
single cell, reveal heterogeneous expression proles of labelled/selected/passed cells from the same
tumor sample.
On the other hand, computational methods have undergone fast advancement as a result of
information technology development and systems theory maturation. Thus, systematic, ecient,
readily applicable methods help reveal critical signatures of inltrated cells. [Collisson et al., 2011a]
uses LCM coupled with microarray to prole epithelial compartment of PDA, then identied ep-
ithelial specic PDA subtype and subtype specic treatments. [Mott et al., 2015] then uses
Non-negative Matrix Factorization (NMF) method to computationally dissect both epithelial and
stromal factors from a heterogeneous collection of pancreatic tumor samples and associates them
with patient survival. In glioblastoma, [Kuhn et al., 2011b] extracts cohort-level cell type spe-
cic dierentially expressed genes using a Population-specic expression analysis (PSEA), a linear
regression based deconvolution method using cell typse exclusively expressed marker genes as ref-
erence, reveals Dierentially Expressiong Genes (DEGs) that were not discovered by bulk DEG
analysis.
Yet, studying tumor heterogeneity continues to be a challenge, associating compartmental spe-
cic functions with clinical outcome remains demanding. Though Fluorescence-Activated Cell
Sorting (FACS) based single cell RNA-seq has been widely applied, antibodies to specically la-
bel cancer inltrated cells are still unavailable, thus refraining such in-depth investigation on such
cells. This situation is worsen in some cancer cells whose biochemical properties have been changed
so that regular antibodies would not success in tagging. Without tagging, experimental physical
isolation of cancer inltrated stromal cells is also dicult as of tissue connectivity, thus single cell
expression proling of them is severely lagged. A seminal example would be that diculty of get-
ting live tumor associated broblasts (TAF) cells impedes understanding of its funciton in tumor
progression. Set aside, rare cell populations, which could be the few resistant cells, might not be
well represented in doing cancer single cell proling due to sampling bias. In addition to these
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experimental challenges, the performance of computational methods has been constrained by the
quality of data upon which models are build. Thus, the study of tumor heterogeneity calls for
innovative methodologies and high-quality data.
1.3 Biological network reconstruction
Contrary to study cells or molecules one-by-one, network biology connects entities by interactions.
Just as people in real world talk to each other to form social network, molecules in a living cell also
\talk" to each other, through physical attaching or functional reacting, forming an interconnected
biological circuit. Depending on molecule types, they constitute dierent types of networks that
perform distinct tasks.
Biological network has many types such as transcriptional regulatory network, signal trans-
duction network, protein-protein interaction and metabolism network. These networks represent
critical interactions in a cell, the smallest functional unit in humans. When a cell respond to either
external signals, such as temperature, nutrients and chemicals, or internal stimulations, such as
metabolism level, DNA damage, and chemical concentration, it communicates with environment
through pathways to receive, pass and process such signals from cell membrane through cyto-
plasma to its nuclei. These pathways do not work as free-standing stations, but collaborate with
each other to form orchestrated cellular circuits with signals running on [Vert and Chory, 2011].
Thus, a signaling network in a cell represents the signal (energy/chemical) transduction cascade
among the related protein/enzymes such as kinases, phosphatases or receptors. Downstream of
this signaling machinery is the genetic information coded in DNA sequence. The sensing and re-
sponding in DNA level is usually performed by a specialized protein called Transcription Factors
(TF). Thus, the activity of TF can therefore be considered as the internal representation of external
environment. The degrees of freedom for this representation is controlled by the number of unique
TFs in a cell. For example, in human cells, this number is around 2000. These TFs control the
read (transcribe) of DNA regions (genes), forming a TF-target network known as gene regulatory
network, or transcriptional regulation network. In short, a true transcription regulatory network
resembles the process controlling DNA segments (gene) transcription into mRNAs by TFs. In par-
ticular, human cancer regulatory networks have been shown to play important roles in uncovering
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disease mechanism, drug mode of actions as well as network-guided medicine [Basso et al., 2005;
Della Gatta et al., 2012; Woo et al., 2015].
Topologically, these networks are composed of nodes and edges, corresponding to biological
entities and their interactions, physical or biochemical. However, the complete network is unknown
even in the simplest eukaryotes. Network reconstruction, also known as reverse engineering, is
to predict the wiring diagram of the interactions based on high-throughput quantication data of
genes, proteins or metabolites. Dierent statistical methods have been used to reconstruct biolog-
ical transcriptional network from gene expression data: [Zhang and Horvath, 2005] rst proposed
a general framework of using correlation-based co-expression method; [Margolin et al., 2006] then
successfully applied information theory based approaches on mammalian cells; [Wang et al., 2009;
Giorgi et al., 2014] demonstrated partial correlation or Gaussian graphical models in eectively
constructing TF-modulator networks; [Pe'er, 2005] formulated appliation of Bayesian network on
proteomics data for signaling network reconstruction. [Hill et al., 2012] later implemented dynamic
bayesian networks using Reverse Phase Protein Array (RPPA) data and inferred a context-specic
signaling network in cell line. [Wang and Huang, 2014] further overviews major methods develop-
ment concept in using high-throughput genomics data to generate signaling networks. Additional
methods are developed for signaling network to account for the dierence from gene expression,
they includes but are not limited to: i) motif-based methods such as NetworKIN [Linding et al.,
2008]; ii) structure-based algorithm such as PrePPI [Zhang et al., 2012]; 3) knowledge-base stategies
such as Phospho.ELM [Diella et al., 2004].
Information theory based strategies are particularly successful. The theory was rst proposed
by Claude E. Shannon in 1948 to nd fundamental limits on signal processing and communication
operations. The similarity between electronic signal system and biological system allows infor-
mation theory's application in both eld. With exceptional ability to capture associations in a
network, it outperforms other methods by recovering non-linear relationship. Dierent information
theory quantications, such as mutual information (MI), conditional mutual information (CMI)
and Kullback-Leibler (KL) divergence, are widely used to quantify dierent types of biological
connections. A reverse engineering algorithm - ARACNE - successfully applied Mutual Infor-
mation (MI) to quantify associations between TF and target gene and reconstructed regulatory
network in human cancers which elucidated mechanisms of carcinogenesis [Pomeroy et al., 2002;
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Floratos et al., 2010; Wang et al., 2013; Aytes et al., 2014; Brichta et al., 2015]. Other CMI-based
algorithms elucidates associations given a third party. Cupid [Chiu et al., 2015] reverse engineered
modulator networks between competing microRNAs and elucidated microRNA regulatory mecha-
nisms. MINDy/Cindy [Wang et al., 2009; Giorgi et al., 2014] build up transcriptional modulators
and targets associations that outlines TF-combinations in regulating targets. DeMAND [Woo et
al., 2015] uses KL divergence and successfully infers drug Mode of Action (MoA) based on a given
interactome.
High-throughput omic quantications not only provide resources to build networks, but also
help to validate these network inference. Modern systems biology started with DNA microarray
quantication (1990s), accelerated with next generation sequencing (2000s), expanded with high-
throughput MS/MS. Recently, third-generation sequencing quanties long DNA sequence. Multi-
plexing global proteome quantication now reduces cost while enhances accuracy allows validation
of peptides quatity validation. Besides, systematic perturbations of model systems can quantify
potential genetic interactions that are associated with specic phenotype [Costanzo et al., 2016].
However, stacked data and accumulated information do not necessarily lead to more knowledge
if there is no ecient ways of hypothesis generation and testing. Likewise, high-throughput data
that representing biological systems is not possible for eye-balling or direct manual read-through.
With great needs and passions to fulll them, cancer systems biology is ourishing. New technolo-
gies, such as CRISPER, ATAC-seq and multiplexing MS/MS, the ability of generating large-scale








Bulk tumor tissues comprise intermixed populations of neoplastic cells and multiple lineages of
stromal cells. We used Laser Capture Microdissection (LCM) and RNA sequencing to disentangle
the transcriptional programs active in the malignant epithelium and stroma of Pancreatic Ductal
Adenocarcinoma (PDA). This led to the development of a new algorithm (ADVOCATE - Adaptive
DeconVolutionOf CAncer Tissue Expression) that accurately predicts the compartment fractions
of bulk tumor samples and can computationally purify bulk gene expression data from PDA. We
also present novel stromal subtypes, derived from 110 microdissected PDA stroma samples, that
were enriched in extracellular matrix- and immune-associated processes. Finally, we applied AD-
VOCATE to systematically evaluate cross-compartment subtypes spanning four patient cohorts,
revealing consistent functional classes and survival associations despite substantial compositional
dierences.
2.2 Introduction
2.2.1 Pancreatic Ductal Adenocarcinoma (PDA) heterogeneity
Solid tumors are heterogeneous populations that contain varying proportions of both transformed
malignant cells and non-transformed stromal cells in varying portions [Aran et al., 2015a]. Pan-
creatic ductal adenocarcinoma (PDA) is among the most stroma-rich cancers, with a complex
inammatory microenvironment that typically predominates the tumor parenchyma. PDA is a
common, aggressive malignancy that responds poorly to therapeutic intervention. As of 2017,
it is the cause of over 42,000 deaths per year in the United States [Oberstein and Olive, 2013;
Siegel et al., 2016]. Within the stromal compartment of PDA, diverse broblast, myeloid, lymphoid,
endothelial and other cell lineages contribute to both pro- and anti-tumor processes, including an-
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Figure 2.6: Heterogenerous Pancreatic Ductal Adenocarcinoma (PDA) microenvironment. Figure adapted
from [Aran et al., 2015a]
giogenesis and epithelial dierentiation [Rhim et al., 2014b], tissue stiness [Jacobetz et al., 2012;
Provenzano et al., 2012], drug delivery [Olive et al., 2009], and local immuno-suppression [Vonder-
heide and Bayne, 2013] (Figure 2.6). These functions are orchestrated through a host of paracrine
signals that pass between and within the epithelial and stromal compartments- communication
that is quickly altered upon tissue disruption. Thus, eorts to parse transcriptional programs of
PDA should take into account the processes active in both compartments, ideally in an in situ
context. Despite extensive genomic characterization [Bailey et al., 2016; Biankin et al., 2012;
Jones et al., 2008; Waddell et al., 2015; Witkiewicz et al., 2015], genetic alterations have thus far
failed to provide conrmed prognostic or therapeutic information for PDA. Indeed, only a small frac-
tion of pancreatic tumors is predicted to harbor druggable genetic alterations [Bailey et al., 2016;
Witkiewicz et al., 2015]. As an alternative to genetic biomarkers, transcriptional classiers for
PDA have been explored using bulk tumor samples [Bailey et al., 2016; Mott et al., 2015;
Collisson et al., 2011a]. While each study diers in the number of subtypes described, their consen-
sus message is that ductal pancreatic tumors include at least two groups distinguished by markers
of epithelial dierentiation state, with the more poorly-dierentiated subtype (i.e. Basal-like, Squa-
mous, or Quasi-Mesenchymal) exhibiting reduced overall survival. However, the classiers identied
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within each cohort do not yield reproducible dierential survival associations when applied to exter-
nal datasets, undermining their potential contribution to determining patient prognosis in a clinical
setting. We propose this ambiguity arises, at least in part, as a consequence of the variable number
of stromal cells present within the tumors of dierent cohorts. In order to test this hypothesis,
we endeavored to directly prole gene expression from puried neoplastic epithelial and stromal
samples isolated from frozen human PDA samples.
Several experimental techniques may be employed to isolate dierent cellular fractions, in-
cluding magnetic separation, Fluorescence assisted Cell FSorting (FACS), and Laser Capture
Microdissection (LCM). The rst two techniques rely on population-specic antibodies to separate
a suspension of cells following disruption of the tumor. Unfortunately, the extremely brotic extra-
cellular matrix of PDA necessitates prolonged enzymatic digestion to achieve a single-cell suspen-
sion, during which time transcriptional proles will be altered. Moreover, PDA diusely inltrates
the surrounding pancreatic parenchyma [Hruban et al., 2007] so that even tumor samples enriched
by FACS for epithelial markers can include contributions from normal, atrophic, pre-neoplastic,
or metaplastic epithelial cells. Laser capture microdissection (LCM) provides a powerful solution,
allowing the isolation of relatively pure compartment-specic tissue samples based on morphologi-
cal distinctions without disrupting the delicate interplay of intercellular communication. However,
performing LCM while maintaining RNA quality suitable for sequencing is technically challenging,
costly, and labor intensive. As a result, there are few examples of large collections of cancer gene
expression proles derived from LCM samples.
2.2.2 Deconvolution methods
Deconvolving bulk samples represents the process of reversing the eects of convolution on recorded
data. In processing bulk gene expression signal, deconvolution means to separate the contribution
of each cell types constituting the bulk sample, inferring their constituent fractions and the respec-
tive expressions. It has becoming an important technique in cancer research eld as it can help
to understand tumor heterogeneity. A recent approach for enumerating cell proportions names
CIBERSORT provided estimations for 22 immune subsets and has since been widely applied to an
array of cancer types [Newman et al., 2015]. Based on aymetrix proling of cultured cells that
are cultured in vitro, the training data lost in situ biology where cells are surrounded by in vivo
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microenvironment. While the the support vector regression used by CIBERSORT achieves good
performance, it lacks interpretability. Acutally, most deconvolution methods rely on a reference
signature gene expression matrix for the inferred cell types. Not until recently, these methods have
been limited to microarray studies and thus are not directly applicable to large cancer research
cohort such as TCGA and ICGC. For specic cancer types such as glioblastoma, an algorithm
called population-specic expression analysis (PSEA) based on marker genes of specic cell types
were used as reference, identifying dierentially expression genes across dierent cell types [Kuhn
et al., 2011a]. However, this method relies heavily on an strong assumption that the marker genes
are exclusively expressed for each cell types constituting bulk samples, which is not always true,
limiting its generalizability. Method based on gene signatures is also developed in a pan-cancer
study, predicting tumor purity method based on curated stromal and immune gene signature [Aran
et al., 2015a], but it fails to estimate purity for Pancreatic Cancer as suggesting in their original
paper probably because of high desmoplasia in pancreatic tumor comparing to all other tumors in-
cluded in their study. Besides those established models, a general framework based on Nonnegative
Matrix Factorization (NMF) was widely used in dierent context to understand the contributing
factors for a collection of highly heterogeneous samples. Together with functional enrichment, it
helps to understand the biological components in a group of patients, but require tuning/re-analysis
each time for dierent dataset [Mott et al., 2015]. In summary, all those computational methods
were limited in at least one of the following aspects: 1. Biased learning data set which did not
capture the heterogeneity in tumor cells or constrained by marker gene robustness; 2. Limited by
biological interpretation of either the prediction or the contribution of genes; 3. Limited by strong
assumption on linear mixing of cell types.
2.2.3 Introduction of ADVOCATE
The problem of predicting inltrated cell fractions given experimentally produced cell type proles
is a typical supervised machine leanring question (Figure )
In this work, a collection of gene expression proles of laser capture microdissected malignant
epithelium and stroma is presented here, for the rst time, with matched reactive stroma, for
65 human pancreatic tumors. These data informed the development of a novel computational









I used to extend my analyses to external datasets. ADVOCATE may be used to perform two
specic functions on bulk tumor expression proles. First, it can infer the fractional contribution
made by each compartment to the original bulk sample. Second, it can transform a bulk tissue
transcriptome into separate proles for each sub-compartment. Though prior approaches exist for
similar applications [Abu-Alainin et al., 2016; Kuhn et al., 2011a], they make several assumptions,
such as the linear mixing of compartments and the specicity of marker genes, that lead to reduced
performance relative to ADVOCATE. Furthermore, a crucial feature is that ADVOCATE can infer
subpopulation-specic expression proles on a sample-by-sample basis, a key capability for use in
a clinical setting.
Previous studies has shown that signaling cascades initiated by oncogenic drivers such as mu-
tant K-ras aects profoundly stromal biology [Ying et al., 2012a] leading to the implicit assumption
that epithelial signaling must guide the dominant transcriptional programs of the stromal compart-
ment. However, if that is true, then the subtypes identied from proling stromal gene expression
will not provide additional prognostic information beyond that derived from the epithelial com-
partment. In this study, I employed the ADVOCATE algorithm to study transcriptional programs
in the epithelium and stroma of PDA across multiple large datasets. Contrary to expectations, I
found a complete absence of association between molecular subtypes in the epithelium and stroma
of PDA. Moreover, I found that purifying the gene expression from each compartment through
transcriptional deconvolution improved the association of existing molecular classiers with overall
survival. Finally, I demonstrated that incorporating molecular subtypes from both the epithelial
and stromal compartments into a combination classier led to the identication of subtypes that








































Figure 2.7: Outline of the ADVOCATE framework. LCM-RNA-Seq proles are used to model genome-wide
gene expression distributions for each gene in across compartments. Bulk tissue proles can be deconvolved
using compartmental gene-wise probabilities, yielding two products: i) predicted compartment fractions in
the bulk tumor and ii) virtual gene expression proles for the epithelium and stroma of that sample. Numbers
indicate steps described in main text.
2.3 Materials and Methods
2.3.1 Samples studied
Information is provided from a total of 129 PDA patients who underwent surgery at the Columbia
Pancreas Center. Of these, LCM-RNA-Seq data are presented for both the epithelium and stroma
of 64 cases, bulk RNA-Seq data are presented for 9 cases, and both LCM and bulk RNA-Seq
are presented for 6 cases. Patients provided surgical informed consent which was approved by a
local ethics committee (IRB #AAAB2667). Samples were frozen intraoperatively by the Columbia
University Tumor Bank.
Freshly frozen tissue samples of PDAC (n = 129) were obtained from surgical specimens from
patients who were operated at the Pancreas Center at Columbia University Medical Center. The
clinical data of these patients are shown in Supplementary Tables C.2. Prior to surgery, all patients
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had given surgical informed consent, which had been approved by the local ethics committee.
Immediately after surgical removal, the specimens were sectioned and microscopically evaluated
by the Columbia University Tumor Bank (IRB AAAB2667). Suitable samples were transferred
into OCT medium (Tissue Tek) and snap frozen in a 2-methylbutane dry ice slurry. The tissue
blocks were stored at 80C until further processing. PDA samples in the Tumor Bank were screened
for diagnosis, purity viability by H&E analysis of frozen blocks. Overall sample RNA quality was
initially assessed by the Pancreas Center supported Next Generation Tumor Banking program by
gel electrophoresis, with samples exhibiting high RNA quality utilized for subsequent analyses.
2.3.2 Sample extraction
Frozen tissue specimens were cut at 8-9 m thickness and 2-3 sections were transferred onto a PEN
membrane glass slide (Arcturus, applied biosystems). For initial histopathological review, imme-
diately adjacent sections were cut and stained using a standard Hematoxylin and Eosin protocol
to conrm the diagnosis and identify suitable areas for either laser capture microdissection or
macrodissection.
2.3.3 Laser capture microdissection and RNA sequencing
Cryosections of OCT-embedded tissue blocks were transferred to PEN membrane glass slides and
stained with cresyl violet acetate. Adjacent sections were H&E stained for pathology review. Laser
capture microdissection was performed on a PALM MicroBeam microscope (Zeiss), collecting at
least 1000 cells per compartment. RNA was extracted and libraries prepared using the Ovation
RNASeq System V2 kit (NuGEN). Libraries were sequenced to a depth of 30 million, 100bp, single-
end reads.
Throughout the staining procedure, RNAse-free water was used. Fixation occured in 95%
ethanol, followed by cresyl violet acetate staining (1% in Tris-buered 70% ethanol), a brief washing
step in 70% ethanol and a nal dehydration in 100% ethanol. Laser capture microdissection was
performed on a PALM MicroBeam microscope (Zeiss) to collect at least 1000 cells per compartment
from selected malignant areas.
26
2.3.3.1 Macrodissection
For bulk tumor sections, areas containing predominantly normal or atrophic pancreas, lymphatic
aggregates, larger blood vessels or nerves were trimmed by removing such regions from the frozen
section on a PEN membrane glass slide using a sterile scalpel, thereby allowing for the enrichment
of tumor epithelium and adjacent stroma from bulk tumor sections. For both methods, cells were
transferred to RLT plus buer (Qiagen) at the end of the procedure and lysis was allowed to
continue for 30 min at RT.
2.3.3.2 RNA
RNA was extracted using the RNeasy Plus Micro Kit (Qiagen) following the manufacturers instruc-
tions. Prior to further processing, RNA integrity and yield were determined using the Agilent 2100
Bioanalyzer (RNA 6000 Pico Kit for LCM and RNA 6000 Nano Kit for bulk samples, respectively).
Yields ranged from 1 to 10 ng per LCM sample and several g per bulk sample, respectively. Only
samples with a RNA Integrity Number (RIN) of at least 7 were used for further processing.
2.3.3.3 RNA amplication and library preparation
For microdissected samples, 1 - 2 ng of RNA from LCM samples were amplied using the Ovation
RNA-Seq System V2 Kit (NuGEN) following the manufacturers instructions. The resulting cDNA
libraries were fragmented using a Covaris S2 Sonicator. For samples that underwent macrodis-
section, a minimum of 200 ng of total RNA underwent a poly-A pull-down to enrich for mRNAs
which then were used as input for the Illumina TruSeq RNA prep kit. Both types of samples
were prepared for the Illumina HiSeq 2000 platform using a Beckmann-Coulter Roboter and the
SPRIworks Fragment Library Kit I. Completing the preparations, a PCR using the KAPA PCR
Amplication Kit was carried out. The libraries were then sequenced at the Columbia Genome
Center to generate 30 million single-end reads of 100 bp length.
2.3.3.4 RNASeq analysis
Reads were mapped to the human reference genome (NCBI/build 37.2) using Tophat (Version
2.0.4) [Trapnell et al., 2009] and two methods of gene expression quantication were employed with
standard settings: (i) HTSeq [Anders et al., 2014] to obtain raw read counts per gene and (ii)
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Cuinks [Trapnell et al., 2012] (version 2.0.2) to obtain fragments per kilobase of exon per million
reads mapped (FPKM) per gene and transcript, respectively. The RSeQC package [Wang et al.,
2012] was used to evaluate the suitability of RNA-Seq libraries for further analysis.
2.3.4 ADVOCATE algorithm
2.3.4.1 Data processing.
Raw counts from LCM RNA-Seq were normalized using the variance stabilizing transformation
(VST) from the DESeq2 R package [Love et al., 2014] after ltering out genes with less than 5
reads in 50% of samples, with the settings varianceStabilizingTransformation(obj, blind = FALSE).
Z-score transformation was then used to scale gene expression level across all samples.
2.3.4.2 Notations
 xb, xe, xs: bulk, epithelial and stromal gene expression.
 De(), Ds(): Gaussian probability density function (PDF) of the epithelial and stromal com-
partments
 #p ; pe; ps; pr: gene-wise fractions. The rst is a vector representing the epithelial, stromal,
and residual (i.e., Residual compartment) fraction of the expression of one gene, with length
of the compartment number; the second to fourth variables represent the epithelial, stromal,
and residual compartment fraction, respectively.
 e; s; e; s; : the rst two variables are sample mean expressions of one gene for epithelial
and stromal compartment, respectively. The third, fourth and last are standard deviations
for the epithelial, stromal compartment, and global, respectively.
 (): Gaussian Cumulative Density Function (CDF) from training set analysis.
 : user-specied prediction accuracy parameter. A smaller  represents a higher prediction
accuracy. For example,  = 0:1 represents a maximum of error 10% for sample fraction
prediction.
 k: number of compartments, i.e. k = 2 or k = 3
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 C: solution space dened by 1 and k.
 #! , !i: weights vector for all solutions (C) given a prediction accuracy () and number of
compartments (k). # !0 is the initial uniform distribution, representing that all solutions have
equal chances of being the optimal solution. !g;i represents weight for the i
th solution in C
after g iterations.
 lgj : loss function of j-th solution at gth iteration.
 : set of n dierentially expressed genes.
 : learning rates, a vector of size n. It is parameterized by the p-value derived from the
negative binomial test between the epithelial and stromal LCM training samples. Each gene
has a dierent . g = 1 represents no learning. g = 0:5 represent the maximum learning
rate, which is the learning rate of the top g.
  : threshold used in the three component model. If both xb is out of the range dened by
[ 1  (), 
 1
+ ()], then pr has a non-zero value.
 #c : a vector of length k with norm = 1. So c = [ce; cs] for k = 2.
2.3.4.3 Approach
The foundation of the ADVOCATE algorithm is the use of a Machine Learning based boosting
algorithm to combine weak evidence derived from the expression of individual genes into a model
that provides an optimal estimate of the compartment-specic composition of a heterogeneous
bulk tissue. The approach assumes that the gene expression probability density function (PDF)
of the bulk is modeled as a mixture of two distinct PDFs, representing the stromal and epithelial
compartments, with the optional inclusion of a third \residual" or \unspecied" compartment. The
latter can be used to model either inltration by an unknown tissue type in a specic sample or the
contribution of a platform-specic bias. Inclusion of the additional compartment allows eectively
addressing variability that is not statistically independent across all genes (i.e., uncorrelated noise),
thus improving prediction of epithelial and stromal specic compartment representation.
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2.3.4.4 Learning



















2.3.4.5 2-component model gene-specic fraction prediction
In a 2-component model, the bulk expression PDF of a gene is assumed to be the weighed sum of
its epithelial and stromal PDFs only.
µ- µ+
MLELR LR
Figure 2.8: 2-component model
Likelihood (MLE) The objective function here is to identify the parameters so that the prob-
ability of observing a given compartment-specic distribution for each gene is maximized.
argmax( De(Xe = xe)  Ds(Xs = xs) ) (2.2)
8>>><>>>:
pexe + psxs = xb
pe + ps = 1
pe  0; ps  0
(2.3)
Xe = D(e; ) ;Xs = D(s; ) (2.4)
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Rewriting object function (Equation 2.2) using Equation 2.1, we have:
argmax( De(Xe = xe) ^ Ds(Xs = xs)) ! (2.5)














In this context, we dene:
  = min(e; s)
+ = max(e; s)
Based on Maximum Likelihood Estimation (MLE), the above equation reaches a minimum for
xe = e and xs = s (2.7). Thus, substituing in Equation (2.3), one has:
pe  e + (1  pe)  s = xb (2.8)
pe  (e   s) = xb   s (2.9)
pMLEe =
xb   s
e   s (2.10)
Likelihood Ratio (LR) It is easy to observe that in Equation (2.10), pe is only dened positive
for xb 2 ( ; +).
When xb   , we use the likelihood ratio between Qe = De(Xe = xb) and Qs = Ds(Xs = xb) to
compute pe. Here, Qe;Qs represent likelihood before normalization.
Qe = e(xb) (2.11)
Qs = s(xb) (2.12)
After normalization and substitution, we have equation (2.13).
pe =
Qe
Qe +Qs ; if xb 2 (  8;  ] (2.13)
when xb  +, an identical approach can be used. Thus, we have equation (2.14) to compute




e s ; if xb 2 ( ; +)
1 Qe
2 Qe Qs ; if xb 2 [+; 8)
Qe
Qe+Qs ; if xb 2 (  8;  ]
(2.14)
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ps is calculated using Equation 2.15.
ps = 1  pe (2.15)
Thus, the compartment-specic contribution to the expression of gene g is given by (Equation 2.16):
#p = [pe; ps] (2.16)
Algorithm 1: Gene-specic compartmental fraction inference








3 Qe = e(xb); Qs = s(xb)








8 ps = 1  pe
9 return #p = [pe; ps].
2.3.4.6 3-component model gene-specic fraction prediction
In a three-component model, the bulk PDF of a gene is computed as a mixture of its epithelial
PDF, its stromal PDF and the PDF of an additional \residual" or \unspecied" compartment. The
latter is used to account for correlated variability across genes due to sample-specic inltration of
unknown tissue or introduction of platform-specic bias.
Use of a 3-compartment model is formulated by specifying a threshold  to determine a range of
bulk gene expression ([x-(); x+()]) that can be eectively modeled using only the epithelial and
stromal PDFs, i.e., where the probability of bulk expression is greater than  (e.g.,  = 10 5).





Figure 2.9: 3-component model
8>>><>>>:
pexe + psxs + prxr = xb
pe + ps + pr = 1
pe  0; ps  0; pr  0
(2.18)
Xe = D(e; );Xs = D(s; ) (2.19)
MLE and LR when xb 2 [x (); x+()], Equation (2.14) still applies, with pr = 0.









Adjusted Likelihood when xb < x () <   or xb > x+() > +, we dene pr = 1 Qe  Qs,
with Qe and Qs representing the epithelial and stromal fractional composition likelihoods before
normalization. Thus, Equation 2.24 follows.
Qe = De(xb); Qs = Ds(xb) (2.23)
pr =
8<: 1 Qe  Qs; xb 2 (  8; x ()) [ (x+(); 8)0; Else (2.24)




e s ; if xb 2 ( ; +)
Qe
Qe+Qs ; if xb 2 [x  ;  ]
1 Qe
2 Qe Qs ; if xb 2 [+; x+()]
Qe; if xb 2 (  8; x+())






+   ; if xb 2 ( ; +)
Qs
Qe+Qs ; if xb 2 [x ();  ]
1 Qs
2 Qe Qs ; if xb 2 [+; x+()]
Qs; if xb 2 (  8; x ())
1 Qs; if xb 2 (x+(); 8)
(2.26)
This allows estimating the compartment-specic fractional composition #p , as in equation 2.27.
#p = [pe; ps; pr] (2.27)
2.3.4.7 Sample-specic fraction prediction
Based on the machine learning theory proposed by Yoav Freund [Freund and Schapire, 1997], a
multiplicative weighted-majority procedure was designed to integrate individual weak evidence rep-
resented by compartment-specic fractional composition predicted on an individual gene basis to
predict an optimal compartment-specic fractional composition for the whole sample #c with a
maximum, user-specied prediction error ().
After running the algorithms 1 or 2, the individual gene-specic fractional composition values ( #p )
are used as an input to the nal evidence integration step, as represented by algorithm 3.
ADVOCATE boosting procedure starts by creating an initial solution space (C) with a set of
solutions such that at least one of them is guaranteed to be within an  of the true solution. The
dimensionality of this space is determined by k = 2 or k = 3. A set of weights !0 representing
the posterior probability of each solution in C is initialized to a uniform distribution. The total
number of solutions (Nk 1 ) grows as  becomes smaller and with increasing values of k.
Given ; for k-component model
C := [0; ; 2; : : : ; 1]k 1
#! 0 := [
k 1]
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Algorithm 2: Gene-specic compartmental fraction inference
Input: xb, De(e; 2), Ds = (s; 2),
Output: #p = [pe; ps; pr]







4 pr = 0
5 Qe = e(xb); Qs = s(xb)
6 x () = min( 1e (); 1s ());












11 pr = 0







15 pr = 0
16 if xb < x () then
17 pe = Qe
18 ps = Qs
19 pr = 1 Qe  Qs
20 if xb > x+() then
21 pe = 1 Qe
22 ps = 1 Qs
23 pr = 2 Qe  Qs
24 return #p = [pe; ps; pr].
35
C2 represents the solution space for a 2-compartment model, when  = 0:1, degree of freedom = 1,
thus, learning on 1-D 240 0:1 0:2 : : : 0:7 0:8 0:9 1
1 0:9 0:8 : : : 0:3 0:2 0:1 0
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The !10 vector for C
2 is thus:h
0:0909 0:0909 0:0909 : : : 0:0909 0:0909 0:0909 0:0909
i
C3 for represents the solution space for a 3-compartment model when  = 0:1, degree of freedom
= 2, thus learning on 2-D. 26664
0 : : : 0:1 : : : 0:5 : : : 0:9 1
0 : : : 0:1 : : : 0:1 : : : 0:1 0
1 : : : 0:8 : : : 0:4 : : : 0 0
37775
The !20 vector for C
3 is thus:h
0:015 : : : 0:015 : : : 0:015 : : : 0:015 0:015
i
Then, ADVOCATE iteratively updates the weight vector #! g for each gene based on the loss function
(see Equation 2.29). Here  is the learning rate, as parameterized by the p-value of the dierential
gene expression analysis.
#! g =
#! g 1  Lgg (2.28)
Lg;i = jCk 1i   pk 1g j (2.29)
g / F(Pvalueg); g 2 [0:5; 1] (2.30)
After all iterations are completed, the solution with the maximum weight ( #! g;i) is chosen as the
predicted sample-specic fraction compositon ((c)) (Equation 2.31).
i = argmaxi2[1;Nk 1 ]
#! g (2.31)
#c = Cki (2.32)
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Algorithm 3: Prediction of sample-specic fraction
Input: , #p ,
#
 ,, k
Output: Sample compartmental fraction c
1 C = f0; ; 2; : : : ; 1gk 1 /*C is the solution space, ci = i   is the i-th solution */
2 !0 = (
k 1; : : : ; k 1) /* Initializing weights with uniform distribution over all solutions/





4 for g   do
5
#p g = result from algorithm 1 or 2
6 for g   do
7 for i  Nk 1 do
8 Lgi = jCi   #pgj /*Loss function of i-th solution at gene g */ !i = (!g 1)i  
Lgi
g
/*update weights according to loss function */
9 Normalizing #! = (!1; : : : ; !Nk 1 ) to get updated
# !g
10 i = maxif!ig
11 return #c = Ci /* The i-th solution has maximum weight. */
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2.3.4.8 Extracting compartmental specic expression
For genes 2  , we have
xg;e = xg;b  pg;e (2.33)
xg;s = xg;b  pg;s (2.34)
For genes =2 , we have
xg;e = xg;b  ce (2.35)
xg;s = xg;b  cs (2.36)
2.3.5 Power Analysis
In order to evaluate the impact of sample size on prediction accuracy, random sub-sampling of 60
LCM pairs was carried out by varying sample sizes from 5 to 60 at an interval of 5. For each sample
size except 60, 100 random samples were drawn. ADVOCATE was trained using the expression
of sub-selected paired LCM samples and, subsequently, used to predict the compartment fraction
of all LCM samples. The prediction error was calculated by considering all epithelial and stromal
LCM samples to be 100% and 0% epithelial, respectively.
2.3.6 Computational validation
2.3.6.1 In silico datasets.
60 pairs of simulated compartmental LCM expression proles were generated by random sampling
from a Gaussian distribution parameterized by each genes mean expression in all epithelial and
stromal LCM samples, respectively, as the means and each genes global variance across compart-
ments as the variances. Synthetic bulk GEP were then generated by linearly mixing simulated
epithelial and stromal expression proles at dierent fractions, ranging from 1% to 99% epithelial
fraction with and increment of 1%. Semi-synthetic bulk samples were generated by mixing actual
paired compartment-specic LCM GEP following the same mixing procedure.
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2.3.6.2 Computational validation procedure.
Compartment fractions from synthetic and semi-synthetic bulk datasets were predicted by training
ADVOCATE using simulated and real LCM expression, respectively. Prediction error was calcu-
lated between predicted epithelial fractions and the original mixing proportions for synthetic and
semi-synthetic data, respectively. For Leave-One-Out Cross Validation (LOOCV), ADVOCATE
was trained using all but one pair of samples and tested on the left-out pair. For Monte-Carlo Cross
Validation (MCCV), ADVOCATE was trained using randomly selected 70% pairs of samples, and
tested on the remaining 30% of pairs for 100 times. For LOOCV and MCCV, it was calculated by
assuming 100% epithelial and stromal cells, respectively, in each paired sample that was tested.
2.3.6.3 Comparison to algorithms.
To quantify the tumor purity for all the aforementioned synthetic and semi-synthetic bulk GEP,
LCM GEP, and actual bulks GEP, we used the R package `estimate' [Aran et al., 2015b] with
`GeneSymbol' as id mapping and `illumina' as platform. The parameters for calculating tu-
mor purity based on ESTIMATE scores were set to the default values (a = 0:0001467884; b =
0:6049872018). Aymetrix LCM data used in Yoshihara et al. were downloaded from the Gene
Expression Omnibus (GEO) using the `GEOquery' package [Davis and Meltzer, 2007] and accession
numbers GSE14548, GSE10797, GSE9890 and GSE29156. Calculations of stromal, immune and
ESTIMATE scores with consequent tumor purity estimations were carried out as described above
by selecting `aymetrix' was chosen as platform setting with the rest of the parameters as default.
To further evaluate algorithm performance, we compared the all predictions from ESTIMATE,
PSEA [Kuhn et al., 2011b], DSA [Zhong et al., 2013], and DeconvRNAseq [Gong and Szustakowski,
2013] with ADVOCATE. We used the marker genes in Figure ??b as the reference genes. R function
lsqnonneg from package R `pracma' was used to solve linear equations in PSEA, the same way as
suggested by [Kuhn et al., 2011b]. R function `solve' from `MASS' function was used to compute
weights for DSA. Raw-counts of 60 pairs of training LCMs together with the same DEGs used in
ADVOCATE training, were used to train DeconRNAseq.
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2.3.7 Experimental validation
2.3.7.1 Assessment of RNA amplication behavior.
In order to test whether RNA amplication using the Ovation RNA-Seq System V2 (NuGEN)
indeed occurs in a linear manner [Kurn et al., 2005], we added ERCC Spike-In Mix 1 (Ambion) at
increasing concentrations (1X, 2X, , 32X - 2 replicates per concentration) to RNA samples before
amplication. ERCC Spike-In Mix 1 contains a collection of 92 synthetic, polyadenylated tran-
scripts between 250 and 2000 bp at dened concentrations. For quantication purposes, the ERCC
Spike-In sequences were added to the reference genome and annotation le, respectively, and the
same Tophat/HTSeq pipeline that was outlined above was used for raw read quantication. Read
counts from libraries containing ERCC Spike-In mix were normalized by accounting for dierences
in library size using the DESeq2 package ( counts(obj, normalized = TRUE) ). ERCC Spike-In
species that did not have at least one read in 80% of the spiked-in libraries were discarded from the
analysis, which left 19 distinct ERCC transcripts, 16 of which could be categorized into 2 major
length categories and 3 major concentration categories in Table C.3. Both normalized reads and
Spike-In concentration were log2-transformed and Pearson correlation was determined at each level
of length and concentration, respectively.
2.3.7.2 LCM samples with bulk expression proles.
Cases for which both paired LCM and bulk GEP were available (n = 6), bulk GEP were deconvolved
into virtual epithelial and stromal GEP, respectively. Pearson correlation was calculated between
the actual compartment-specic LCM GEP and its virtually puried counterpart. Correlation
between randomized bulk and LCM samples served as a control for all the other correlations. The
randomized bulk GEP were generated by shuing gene identiers.
2.3.7.3 Nuclei counting.
15 bulk PDA sections were macrodissected as described above to enrich malignant epithelium and
adjacent stroma. Sections used for RNA extraction and molecular proling were derived imme-
diately adjacent to sections used for histopathological assessment. For each bulk section, 8 - 10
high-power elds were recorded, epithelial and stromal areas identied and subsequently, nuclei
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were counted manually using the ImageJ(11) software and its built-in multi-point tool. Counts
were noted per compartment and divided by the grand total to yield compartmental fractions.
Mean Absolute Percentage Error (MAPE) was used to quantify ADVOCATE prediction accuracy
(Equation 2.37). The epithelial fraction based on nuclear counting or areal summation was consid-







j Vi   Pi
max(Vi; Pi)
j (2.37)
2.3.7.4 Human Protein Atlas (HPA).
Using the HPA search algorithm, we subset the list of potential proteins to those that had high-
est quality antibodies for immunohistochemistry (IHC) by applying the lter ih tissue reliabil-
ity:Supportive. Next, we evaluated IHC staining patterns for PDA tumor sections in the HPA
pathology database for the top and bottom 50 genes of our subset DEG list which represented
mRNA-predicted stromal and epithelial genes, respectively. The observed IHC staining patterns
were categorized as follows: (i) 'strongly supportive' for cases where IHC staining aligned with
mRNA prediction with both high signal intensity and compartment-specicity, (ii) 'weakly sup-
portive' for cases where IHC staining aligned with mRNA prediction with either moderate signal
intensity or moderate compartment-specicity (i.e. dierential expression can be appreciated on
the protein level, but is not bimodal), (iii) 'indeterminate' for cases with absent compartment-
specicity (i.e. no appreciable dierential expression on the protein level), (iv) 'not expressed' for
cases where low or absent signal intensity precluded meaningful analysis, and (v) 'opposing' for
cases where IHC staining contradicted mRNA prediction. The full list of genes that were found to
be deferentially expressed genes between the epithelium and stroma based on mRNA, the list of
genes for which antibodies with high quality for IHC are available at the HPA and the results from
the described analysis can be found in Tables C.4,C.5.
41
2.3.8 ADVOCATE prediction on external PDA datasets
2.3.8.1 Dataset preparation.
The UNC dataset was downloaded using the R package GEOquery [Davis and Meltzer, 2007], and
accession number GSE71729. Only pancreatic primary tumor samples with survival data were
retained for our analysis (n=125). For the ICGC cohort, normalized expression and clinical data
were extracted from the supplementary information provided by Bailey et al [Bailey and Leach,
2012]. After matching sample IDs with phenotypical data, we kept 95 samples for our analysis.
RNA-Seq V2 data was downloaded from the TCGA data portal on 5/31/2016 together with clinical
and biospecimen information - including a report on 27 cases that were retracted after review by
the PAAD EPC. Beside these 27 cases, we excluded cases with a diagnosis of other malignancy.
Raw read counts per gene were extracted from the RSEM output les for all samples, normalized
to account for dierent library sizes, and the variance was stabilized as implemented in the DESeq2
package [Love et al., 2014].
2.3.8.2 Deconvolution on external datasets.
Given the dierent criteria that each of the described external studies used for including PDA
samples for molecular proling together with the substantially larger sample sizes, we expected
a higher degree of tumor tissue heterogeneity and, therefore, employed the three-compartment
ADVOCATE implementation (prediction accuracy) to estimate epithelial, stromal and residual
compartment fractions in these cohorts. Inferred compartment-specic virtual GEP were derived
from the respective bulk GEP using the two-compartment implementation of ADVOCATE as
described above.
2.3.9 Epithelium classier genes.
Clustering of both bulk GEP and virtually puried compartmental specic proles was performed
by sub-selecting the normalized expression data of epithelial classier gene sets described by [Mott
et al., 2015] for epithelial subtypes.
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2.3.10 Stromal signature for clustering.
Stromal LCM-RNA-Seq gene expression proles from 110 patients were VST-normalized as de-
scribed above and subset to stroma-specic genes (as determined from the paired DEG between
epithelium and stroma, genes t-statistic > 0 and FDR < 0:1, respectively, n= 4616). The 1000
most variable genes were determined from 100 bootstraps of the 4616 genes x 110 samples input
matrix based on their median absolute deviation (MAD). The 1000 genes occurring most often
in these 100 bootstraps were used as input for nonnegative matrix factorization (NMF) using the
NMF R package [Gaujoux and Seoighe, 2010] with its standard algorithm (Brunet). The factoriza-
tion rank was estimated from actual and randomized data for 2, 3, 4, 5 and 6 ranks. Cophenetic
correlation and silhouette scores decreased substantially already from 2 to 3 ranks and declined
further for higher factorization ranks. NMF was then run with 200 iterations (nmf(x, rank = 2,
nrun = 200, seed = 1)) and the samples were assigned a cluster by hierarchical clustering of the
consensus matrix using complete linkage. In order to derive a signature distinguishing between the
two subtypes, dierential genes were identied using the siggenes R package (11). Genes with FDR
< 0:001 and either an above median expression or an eect size > 1:5 were retained. The signature
genes and their functional annotation using Gene Ontology Biological Processes and the DAVID
Bioinformatics Resources [Huang et al., 2008] can be found in appendix tables C.6.
2.3.11 Clustering
A Pearson dissimilarity distance metric was used as the input for k-means consensus clustering
for each dataset with the same preset random seed value. Each clustering was run 500 times.
Subsequently, the cluster output from all k-means clustering was hierarchically clustered and the
number of clusters was decided based on the cutree function in R package 'stats`, thereby yielding
the nal results for each dataset and each compartment. Using the average silhouette score, most
robust results were obtained for 2 epithelial and stromal clusters, respectively, in each data set.
For the virtual epithelial GEP in the UNC cohort, both 2 and 3 clusters were equally feasible,
however to be consistent with the number of clusters from other datasets, we selected 2 clusters for
this dataset, too. In order to be consistent with the stromal signature derivation process, stromal
class assignment was carried out using the same NMF and hierarchical clustering pipeline described
above. Provided that experimental produced compartmental gene expression might not perfectly
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represented in bulk expression, especially in external datasets. As expected some CUMC stromal
signature genes were less informative, i.e. showed low variance as determined by their interquartile
range (IQR) in the external cohorts. Therefore, those stromal signature genes exhibiting a below
global variance in a given cohort were removed before clustering.
2.3.12 Gene set enrichment analysis
Gene set enrichment analysis (GSEA) was performed on subsets of gene sets fromMSigDB [Liberzon
et al., 2011] (Hallmark, C2 canonical pathways including gene sets from the Reactome, Biocarta
and KEGG data bases, and C6 oncogenic signatures) using the R package 'GSVA' as described
previously [Hanzelmann et al., 2013]. Results from a dierential enrichment analysis using the R
package 'limma' [Smyth, 2005], including the pathway abbreviations used in the gures, can be
found in the Tables C.6.
2.3.13 Silhouette score and Dierential Gene Expression (DEG)
Silhouette scores were calculated using the silhouette function from the R cluster package with the k-
means clustering results and the Pearson dissimilarity matrix as input. Dierential gene expression
analysis was calculated out using the 'limma' package [Smyth, 2005]. Among all dierentially
expressed genes between compartment-specic subtypes (adjusted p-value < 0.05) the top 50 genes
per subtype were shown in the heatmaps.
2.3.14 Survival analysis
The association of molecular subtypes with disease outcome was evaluated using Kaplan-Meier
survival analysis calculated along with log-log p value using the surv and coxph functions from
the 'survival' package [Therneau and Lumley, 2016]. Furthermore, tting and visualization of Cox
proportional hazards models were carried out using the cph function from the R package 'rms'



























































Figure 2.10: Compartment-specic gene expression proling of pancreatic tumors. (a) Images of Cresyl Violet
stained human PDA frozen sections before and after laser capture microdissection of malignant epithelial
and adjacent stromal cells. (b) RIN values for RNA samples derived from the indicated compartment (N =
60 each). (c) Number of genes and transcripts detected at > 1 FPKM in the samples from (b).
2.4 Results
2.4.1 Transcriptional proling of pancreatic cancer epithelium and stroma
To study the separate transcriptional programs of intact pancreatic tumor epithelium and stroma,
we optimized a robust protocol for maintaining RNA integrity during laser capture microdissection
of frozen tumor tissues, yielding total RNA suitable for library preparation and RNA sequencing.
We rst applied this LCM-RNA-Seq technique to 60 primary PDA specimens that were harvested
and frozen intraoperatively by the Columbia University Tumor Bank in collaboration with the
Columbia Pancreas Center (see Tables S1,2 for patient characteristics). For each tumor, we gen-
erated paired gene expression proles from the malignant epithelium and nearby reactive stroma,
as distinguished by cell morphology Figure 2.10a. Extensive quality control metrics conrmed the
high quality of resulting RNA libraries (Figure 2.10b-c and Figure 2.11a-d.) [Adiconis et al., 2013;
Shanker et al., 2015].
Critically, samples from the two compartments separated spontaneously along the rst com-
ponent of a Principal Component Analysis (PCA) with virtually no overlap, (Figure 2.12a) and
were distinguished by expression of established marker genes for epithelial cells (KRT19, EPCAM,
45
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Figure 2.11: Quality control of the LCM-RNA-Seq pipeline. (a) ERCC RNA Spike-In Mix 1 (Ambion) was
added to LCM RNA samples before amplication at increasing concentrations. The amount of ERCC Spike-
In Mix correlates strongly with the observed ERCC read counts across dierent concentration and length
categories, suggesting that amplication of comparable mRNA species occurs linearly as well. After read
alignment using Tophat (v.2.0.4), BAM les (n = 120, 60 per compartment) were analyzed using the RSeQC
package (v.2.6.2) to quantify: (b) the fraction of aligned reads and uniquely aligned reads, respectively, as
compared to the total number of reads (= 100%) generated for each library, (c) the fraction of reads mapping
to ribosomal RNA genes, as compared to the number of aligned reads (= 100%). (d), the fraction of aligned
reads aligning to exonic, intronic and intergenic regions, respectively.
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Figure 2.12: (a) Principal component analysis of the proles from Figure 2.10c. 60 pairs of epithelial and
stromal LCM samples. Color graduation shows pairing of samples from the same tumor. Three samples
discussed later are labeled. (b) Heatmap showing the dierential expression of marker genes for the indicated
cell types in each sample.
CDH1) versus markers of various stromal cell types, including leukocytes (PTPRC, CD4, CD163),
endothelial cells (VWF, ENG, CDH5), and cancer associated broblasts (CAFs) (ACTA2, DCN,
FAP) (Figure 2.12b). We determined that technical variance was substantially lower than biological
variance (Figures 2.13) and found that dierent malignant areas captured from the same tumor clus-
tered closely, suggesting that inter-tumoral transcriptional heterogeneity outweighs intra-tumoral
heterogeneity (Figure 2.13a-b). In summary, our analysis shows that LCM-RNA-Seq produces
robust, genome-wide, compartment-specic gene expression proles.
We next examined the most dierentially expressed genes between the epithelium and the
stroma (Table C.4) and compared their expression to immunohistochemistry for the corresponding
proteins in The Human Protein Atlas (HPA) pathology database [Pontn et al., 2008]. We restricted
our analysis to proteins for which the highest-quality antibodies were available (n= 321), based on
established HPA criteria. Of these, we evaluated the immunostaining patterns for the 50 genes
whose LCM-RNA-Seq expression was most dierentially expressed for each compartment, examin-
















Technical replicates Same tumor 
(b)
Figure 2.13: (a).Cresyl violet stain of a frozen PDAC section on a PEN membrane slide. Boxes indicate
areas from which epithelial cells were gathered using LCM. The area marked by the dashed line was sampled
from both the section shown and a further serial section from this tumor with at least 50 m distance. These
5 biological replicates (blue) from the same tumor cluster closely in (b).PCA when compared to further
biological replicates from dierent tumors (grey) while technical replicates (red) show virtually identical
behavior in PCA.
patterns for 47 of 50 epithelial proteins and 36 of the 50 stromal proteins (Figures 2.14-a,c, Table
C.5). For example, Figures 2.14-b,d show two members of the galectin protein family, LGALS4
and LGALS1, with inverse staining patterns in the two compartments, consistent with our predic-
tions. Critically, none of the proteins were found expressed in a pattern opposite that predicted;
most genes lacking supportive staining were simply not detected, perhaps due to post-translational
regulation. Thus, through the use of LCM-RNA-Seq, we were able to compile a rich resource of
compartment-specic genes that may be of use as novel markers for the pancreatic cancer eld.
2.4.2 A framework to deconvolve compartment-specic gene expression proles
from bulk data
Multiple large-scale gene expression datasets for PDA have been reported and each has provided im-
portant contributions to our understanding of the disease. However, it has been challenging to make
comparisons between these datasets due to dierences in expression proling platforms, inclusion
criteria, sample preparation, and other technical details. The availability of experimentally-puried,













































































































































































































































































































































































































































































































































































Figure 2.14: (a) Validation of genes predicted as epithelium-specic based on mRNA expression. Bar height
and color shading reects the certainty (t-statistic) of dierential expression. The box color below each
bar summarizes results of immunohistochemistry on PDA sections from the Human Protein Atlas (HPA).
IHC staining pattern was categorized as strongly or weakly supportive of the predicted compartment (blue),
indeterminate (grey), absent (white), or opposite the predicted pattern (black). (b) An example epithelium-
specic gene, LGALS4, showed a protein staining pattern that was strongly consistent with its mRNA
expression (at left). Blue and red arrows indicate PDA epithelium and stroma, respectively. (c) Analysis
of protein expression for genes predicted as stroma-specic based on mRNA expression. (d) An example
stroma-specic gene, LGALS1, was expressed exclusively in the tumor stroma.
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resources by using transcriptional deconvolution to remove the noise introduced by variable tissue
composition in each dataset. I utilized our compartment-specic PDA expression proles to train
a probabilistic algorithm (ADVOCATE), consisting of four steps, as outlined in Figure 2.7: 1)
ADVOCATE ts Gaussian-mixture model on the collection of expression proles on epithelium
and stroma to infer the expression distribution of each gene in each compartment, respectively.
2) When subsequently provided with a bulk gene expression prole, the expression of every gene
in the bulk sample is compared with the expression distribution inferred in Step 1, to derive a
compartment fraction prediction for each detected gene. 3) These fractions are integrated across
all genes to infer a global compartment fraction for the bulk sample. 4) Finally, ADVOCATE
combines the information from steps 1, 2, and 3 to infer compartment-specic virtual expression
proles, theoretically recapitulating the results of more-costly and laborious LCM-RNA-Seq. While
I focus here on the epithelial and stromal compartments of pancreatic cancer, there is no technical
limitation for the number of compartments that can be modeled provided that distinct, matched
compartment-specic expression proles are available.
2.4.3 Computational validation of ADVOCATE performance
I carried out a series of in silico and experimental assays to validate ADVOCATEs performance.
First I generated articial epithelial and stromal gene expression proles by randomly sampling from
the density of expression for each gene across the LCM-RNA-Seq proles for each compartment (see
section 2.3). These were then mixed together in silico in varying proportions to create synthetic
bulk samples with dierent compartment fractions. When ADVOCATE was trained on these
synthetic compartment-specic samples, it predicted the compartmental fractions of the synthetic
bulk samples with error rates of less than 3% (Figure 2.15a). One might assume this test to be
trivial as any algorithm should produce optimal deconvolution from such synthetic data. Yet,
the ESTIMATE algorithm, which is commonly used for compartment fraction analysis [Yoshihara
et al., 2013], signicantly and systematically over-estimated the epithelial compartment fraction,
independent of the actual compartmental mixture (black dotted line in Figure 2.15a).
Next we generated a more realistic set of semi-synthetic bulk samples by computationally mixing
proles from actual LCM-derived epithelial and stromal sample pairs, in varying proportions (Figure
2.15b). Again, ADVOCATE predicted the compartmental mixture rate with very high accuracy
50



































































Figure 2.15: In-silico validation using synthetic data. (a). Compartment fraction analysis performed with
ADVOCATE (green) or ESTIMATE (black) on a computationally generated (synthetic) set of epithelial
and stromal proles mixed together in silico in varying proportions. (b).Compartment fraction analysis
performed with ADVOCATE (green/yellow) or ESTIMATE (black) on a semi-synthetic set of samples gen-
erated by mixing actual experimental pairs of LCM expression proles together in varying proportions, for
each of 60 tumors. The yellow lines highlight three outlier samples.
(>90%) for the majority (80%) of the samples.
In complementary to the simulation analysis, we estimated compartment-specic LCM sample
purity by leave-one-out cross-validation (LOOCV) and Monte Carlo Cross Validation (MCCV)
[Xu et al., 2004]. In LOOCV, the composition of each individual LCM sample was estimated
after training the model on the remaining 59 pairs. Figure 2.16 shows that ADVOCATE correctly
predicted a very high (>90%) epithelial and stromal composition for the majority of compartment-
specic LCM-derived samples (73%), as expected, with the residual error accounted for by both
biological and technical variability in the LCM-derived sample proles. In MCCV, random selection
of 70% of total 60 samples were used as the training to predict the remaining 30% samples. A total
of 100 sampling were run to estimate the prediction variation for each sample. Figure 2.17 showed
the same outliers as LOOCV. All samples have a maximum prediction standard deviation of of
0:012.
Interestingly, the same three outlier samples with >20% error were detected in the analyses
from both Figures 2.15b and 2.16 (orange lines/bars). Careful histopathological examination of
these samples revealed that one (E17) was poorly dierentiated and therefore may plausibly ex-
hibit a more stroma-like signature (Figures 2.19). A second (S10) had large areas of highly cellular
stroma intermixed with brotic regions, which could plausibly lead to a more epithelial-like stroma
51



























































































































































































































































































































































































Figure 2.16: Leave-One-Out Cross Validation of compartment fraction using ADVOCATE where the epithe-
lial (blue) and stromal (red) fractions, are predicted for each individual pair of LCM-RNA-Seq proles after


















































































































































































































































































































































































Monte Carlo Cross Validation of CUMC LCM Stroma
Figure 2.17: Monte-Carlo Cross Validation of compartment fraction using ADVOCATE where the epithelial
(blue) and stromal (red) fractions, are predicted 100 times for remaining 30% of sample pairs of LCM-RNA-
Seq proles after training the model using random 70% sample pairs. The outliers from Figure 2.15 are



















Figure 2.18: Power analysis for training
the ADVOCATE algorithm. Plot shows
95% (dark blue) and 85% (light blue) per-
centile of prediction errors relative to sam-
ple sizes based on LOOCV analysis. Errors
decreases quickly as sample size increases,
stabilize after about 20 samples and reach
a minimum at 60 samples.
(a) (b)
Figure 2.19: Images show hema-
toxylin and eosin stained sec-
tions from samples E17 (a,b).
Scale bars for (a) indicate 200m
and for (b) indicate 20m. Ep-
ithelial cells in sample E17 (ar-
rows) were poorly dierentiated.
E = epithelium; S = stroma.
signature (Figure 2.20). No obvious pathological abnormalities were apparent in the third sample
(Figure 2.21) suggesting either imprecise microdissection or an unusually high level of epithelial
delamination into the stroma [Rhim et al., 2012]. These ndings were consistent with the clustering
of these three samples near the interface between epithelial and stromal samples by PCA (Figure
2.12a). Together, the results provide evidence of the robustness of ADVOCATE in predicting bulk
tumor composition from synthetic data and its resilience when applied to more realistic experi-
mental data. A power analysis performed using the LOOCV technique found that experimental
error diminished substantially as the size of the training set approached 20 tumors, indicating fairly









Figure 2.20: Images show hematoxylin and eosin stained sections from samples S10-(a,b).Scale bars for (a)
indicate 200m and for (b,c) indicate 20m. Sample S10 exhibited stroma with two starkly dierent phenotypes:




Figure 2.21: Images show hema-
toxylin and eosin stained sec-
tions from samples S7 (F). Scale
bar indicates 20m. Sample S7
exhibited histopathology typical


















































Figure 2.22: Predicted compartment
fractions for CUMC epithelial LCM
samples (left) and stromal (right)
LCM-RNA-Seq proles using ADVO-
CATE (red) and ESTIMATE (blue).
2.4.4 Experimental validation of compartment fraction prediction with ADVO-
CATE
I next assessed ADVOCATEs ability to predict the composition of samples whose compartment-
specic composition had been experimentally assessed and compared it to the ESTIMATE algo-
rithm (Figure 2.22). I began by analyzing gene expression proles from pure epithelial and stromal
tissues isolated by LCM on PDA samples. Both ADVOCATE and ESTIMATE correctly predicted
the composition of pure malignant epithelial samples to have a high degree of epithelial identity
(a median of 99.9% and 96.7%, respectively) albeit with slightly larger variance for ADVOCATE.
By contrast, for pure stromal tissue, ADVOCATE drastically outperformed ESTIMATE, assessing
the epithelial fraction at 12.1% in median, compared to 56.1%, respectively.
One could argue that ESTIMATE was original trained on Aymetric gene expression microarray
data, and was a general predictor for tumor purity across cancer types. Thus comparing a context
specic algorithm, ADVOCATE, to it might be lack of fairness. Thus, we compared to additional
three algorithms - PSEA, DSA and DeconRNAseq all of which could be implemented based on
CUMC LCM marker genes (PSEA/DSA) or training data (DeconRNAseq).
First, we applied all ve algorithms to predict the compartment fractions of each of the LCM-
RNA-Seq samples used to train ADVOCATE in our manuscript. ADVOCATE predicts the highest
epithelial fraction for the epithelial LCM samples and the second highest stromal fraction for the
stromal samples, and the highest overall purity for all samples in this LCM dataset. It is dicult
to know whether the slightly increased stromal fraction prediction produced by ADVOCATE on
stroma LCM samples reects error or the eects of low-level contamination of stroma samples
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resulting from delamination of epithelial cells into the stroma, a known phenomenon that has been
widely reported (see Rhim, et. al, 2012, Cancer Cell 25, 735747).
Since ESTIMATE was originally trained on Aymetrix gene expression microarray data rather
than RNA-Seq, we examined the four collections of Aymetrix gene expression data from breast
and ovarian cancer LCM samples reported in the original ESTIMATE manuscript and found a
similar result (Figures 2.24), suggesting a systematic analysis bias toward epithelial identity.
Carcinoma-derived cell lines are often used to provide a pure epithelial reference for gene ex-
pression studies. I used ADVOCATE to predict the compartment fractions of 40 PDA cell lines
in the Cancer Cell Line Encyclopedia (CCLE) [Barretina et al., 2012b]. As expected, all PDA
cell lines were scored as predominantly epithelial with a mean epithelial fraction of 94% (Figure
2.25a). However, nine lines were predicted to have >10% stromal fraction. This should not be
interpreted as an indication of the presence of stromal cells in these lines. Rather, this result
may indicate either that the original tumor was poorly dierentiated or that the cells underwent
epithelial-to-mesenchymal transition (EMT) during adaptation to tissue culture conditions, since
stromal signatures are strongly enriched in mesenchymal genes [Ross et al., 2000]. Consistent with
that interpretation, sarcoma and mesothelioma cell lines (n = 28) were predicted to be signicantly
more stromal than PDA cell lines (P = 2:30e 25, two-sample Kolmogorov-Smirnov (KS) test, Fig-
ure 2.25b). This nding highlights potential issues in the common practice of using epithelial tumor
cells lines indiscriminately as a "pure" epithelial reference for purity assessments.
Finally, to directly test the ability of ADVOCATE to predict compartment fractions from bulk
tissue, we performed RNA-Seq on bulk tissue from 15 PDA samples and compared compartment
fraction predictions to histopathological assessments. To account for the fact that bulk tumor sam-
ples may also contain varying amounts of other tissue types (including normal or atrophic pancreas,
lymphoid aggregates, nerve plexus, and blood vessels, which are routinely found intermixed with
frank carcinoma in pancreatic tumors), I incorporated a third (\Residual") compartment into this
analysis, composed of genes with a low expression probability in both epithelial and stromal com-
partments (see section 2.3). We note that multiple studies have reported discrepancies between tu-
mor purity estimates from pathology review and those from molecular analyses [Carter et al., 2012;
Song et al., 2012; Yoshihara et al., 2013], either as a result of technical limitations or of sampling
dierent areas of the tumor for the respective analyses. To minimize the latter eect, RNA was
56
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Figure 2.23: Comparison of tissue fraction predictions by dierent algorithms, using the (a). CUMC PDA
LCM epithelial and (??) LCM stromal (bottom) sample sets. Depicted as scatter plots by sample ID (left)

















































































































































































Figure 2.24: Reanalysis of compartment-specic expression proles from breast and ovarian cancer generated
by laser capture microdissection and Aymetrix microarrays, from [Yoshihara et al., 2013]. Left panel:
ESTIMATE predictions of epithelial fraction for puried epithelial (blue) and stromal (red) samples, showing
high predicted epithelial content in stromal samples (30% - 70% across all four datasets). Right panel: PCA















































































































































































































































































































































































































Figure 2.25: ADVOCATE compartment fraction predictions for cell lines derived from (a) pancreatic ductal
adenocarcinoma or (b) sarcomas and mesotheliomas. Expression proles were obtained from the Cancer Cell
Line Encyclopedia (CCLE).
extracted from 2 - 3 tissue sections immediately adjacent to that used for histopathology, following
manual trimming of peripheral non-tumor tissues. Two blinded, independent histopathology assess-
ments of tumor composition were performed on hematoxylin and eosin (H&E) stained frozen tissue
sections. First, the areas of epithelium, stroma, and other cells were estimated by a gastrointestinal
pathologist. Second, individual nuclei were counted in the epithelial and stromal compartments
for multiple representative tumor areas (Figure 2.26a). We found that tumor content was highly
correlated between the two measures ( = 0.77), with the area assessment showing lower epithe-
lial content than nuclei counting (Figure 2.26b). ADVOCATEs predictions tracked very well with
nuclei count assessment, with a mean absolute percent error (MAPE) of 12.1% (Figure 2.26c).
However, it systematically overestimated tumor content, relative to area assessments (MAPE =
34.4%, Figure 2.26c), perhaps suggesting that nuclei counts more closely reect gene expression
contributions from distinct compartments.
By contrast, ESTIMATE-based prediction errors were almost double, (Figures 2.27a-b) with
mean absolute percent errors of 24.4% and 54.8% for nuclei counts and area estimates, respec-
tively. These data demonstrate the improved accuracy of ADVOCATE for compartment fraction
estimation from bulk tumor proles.

























































































































Figure 2.26: Experimental validation. (a) Example of nuclei counting for the epithelial (teal dots) and stroma
(orange dots) compartments. Nuclei per compartment were divided by the total to yield the compartmental
fraction. (b - d) Comparison between tumor epithelium content estimated by (C) nuclei counting vs. area
estimation, (b) nuclei counting vs. ADVOCATE, and (c) area estimation vs. ADVOCATE for 15 tumors
from the Columbia University Medical Center (CUMC) collection. MAPE denotes Mean Absolute Percentage
Error as a measure of prediction accuracy.
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Figure 2.27: Compartment fraction predictions of bulk PDA samples using ESTIMATE, compared to (a)
(Left) nuclei counting and (b) (Right). area estimation. MAPE denotes Mean Absolute Percentage Error
as a measure of prediction accuracy.
fraction. As shown in Figure 2.28, again, ADVOCATE achieves the lowest error rate comparing
to nuclei counted tumor purity, outperforming all other 4 algorithms. By contrast, ESTIMATE
over-predicts and deconRNAseq generally under-predicts.
2.4.5 Experimental validation of virtual expression proles generated from bulk
tumors
The second function oered by ADVOCATE is to extract compartment-specic gene expression
data from bulk samples (referred to as virtual proles hereafter). To assess the accuracy of vir-
tual proles, we performed LCM-RNA-Seq on six of the tumors for which abulk gene expression
data were available. We then determined the correlation between the LCM proles and their bulk
counterparts, before and after deconvolution (Figure 2.29). Without deconvolution, there was only
modest correlation with  = 0:59 and  = 0:48 for epithelium and stromal LCM comparisons,
respectively. By contrast, following deconvolution with ADVOCATE, the correlation between ex-
perimental LCM and virtual proles increased signicantly to  = 0:71 for the epithelium and
 = 0:74 for the stroma (P = 1:8e 5 combined, two-sample KS test). As a control, analysis
of permuted proles for each bulk sample found no linear correlation. Critically, expression of
lineage-specic markers in virtual epithelial and stromal samples closely tracked with the results of
experimental microdissection (Figure 2.30a vs. Figure 2.12a). Indeed, both hierarchical clustering
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Figure 2.28: Comparison of tissue fraction predictions by dierent algorithms, using CUMC bulk PDA
samples for which fractions based on nuclei counting are available. Depicted as a scatter plot by sample ID
(left) and boxplot (right). Algorithms are color-coded.
and PCA showed divergence of virtual epithelial and stromal proles relative to the intermediate
clustering of bulk proles (2.30bc). Taken together, these data demonstrate that ADVOCATE is
eective in deconvolving compartment-specic expression proles from bulk tissue.
Finally, we sought to determine whether the ADVOCATE algorithm would perform at a similar
level on samples from another tumor type, making use of a published array expression dataset
derived from laser capture microdissected breast cancer samples [Oh et al., 2015]. We trained an
implementation of ADVOCATE on a subset of these samples and then performed LOOCV analysis,
nding the predicted fraction to be >80% in the vast majority of samples for both compartments
(Figure 2.31. This trend was also apparent when analyzing the remaining samples from the dataset,
with a small number of samples predicted to have intermediate compartment fractions, consistent
with the PCA representation of all LCM samples. These results demonstrate the generalizability






























P = 7.4e-07 P = 1.8e-05
Epithelium
Stroma
Figure 2.29: Correlation of normalized gene ex-
pression between experimental LCM-RNA-Seq
proles and: permuted bulk proles (left, neg-
ative control); bulk expression proles (middle);
and virtual epithelial and stroma proles puried
from bulk using ADVOCATE (right). In each





















































Figure 2.30: CUMC bulk sample expression deconvolution. (a) Heatmap showing expression of indicated
marker genes in virtual epithelial and stromal proles derived from the 15 bulk tumors described in 2.26.








































































































































Figure 2.31: ADVOCATE implementation for breast cancer LCM data. (a). PCA of 82 matched
compartment-specic gene expression proles from breast cancer samples as described by [Oh et al., 2015].
The compartmental origin separates the samples along the second principal component (b). PCA of the ub-
set of the samples space used for training a breast cancer implementation of ADVOCATE (c). Results from
a Leave-one-out Cross-validation (LOOCV) where epithelial samples are predicted to have high epithelial
content (upper panel) and stromal samples are found to have high stromal content. (d). Predicted compart-
mental fractions for test samples that were not used during model training, including those intermingled in
PCA.
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2.4.6 Compartment fraction analysis reveals distinct compositions of public
PDA datasets
Three prior studies have presented expression-based classication frameworks, derived from large
collections of bulk PDA proles, that relate to biological properties or outcome [Bailey et al., 2016;
Collisson et al., 2011b; Mott et al., 2015]. In each study, a subtype exhibiting molecular char-
acteristics consistent with a poorly dierentiated state (termed Quasi-Mesenchymal, Basal-like, or
Squamous, respectively) was shown to have poor overall survival, relative to a Classical or Pro-
genitor tumor subtype exhibiting a signature reective of pancreatic tissue origin, with varying
numbers of additional groups presented in each paper. [Mott et al., 2015] further parsed molec-
ular subtypes from the tumor stroma using non-negative matrix factorization (NMF, a statistical
approach to separating the constituent parts of an object (See Discussion,[Lee and Seung, 1999]).
Each of these reports has contributed to our basic understanding of pancreatic cancer biology, but
a systematic evaluation of compartment-specic contributions is needed to identify subtypes that
are broadly applicable across biologically and technically heterogeneous PDA patient cohorts.
We used the compartment fraction analysis function of ADVOCATE to analyze pancreatic
cancer gene expression proles from three independent cohorts: (a) UNC Chapel Hill (UNC,n =
125), (b) the International Cancer Genome Consortium (ICGC, PACA-AU RNA-Seq dataset, n =
93), and (c) The Cancer Genome Atlas (TCGA, PAAD dataset, n = 137) (see Methods for inclusion
criteria). We used the Unspeciedgroup of the 3-compartment implementation of ADVOCATE
to account for the technical noise introduced by distinct gene expression proling and library
preparation methods as well as the potential inclusion inltrating normal cells, thereby focusing
on the ratio of epithelial to stromal cells in each tumor. Notably, we found that the epithelial
and stromal fractions varied signicantly between the cohorts with 46%, 67% and 55% epithelium
for the ICGC, UNC and TCGA cohorts, respectively (p < 0:001, one-way ANOVA) (Figure 2.32).
This analysis highlights critical dierences in composition between tumor collections curated with
dierent inclusion criteria or enrichment practices.
For the TCGA cohort, I applied the RNA-based algorithms as well as the DNA-based ABSO-
LUTE to predict epithelial fractions for all pancreatic ductal adenocarcinomas samples from TCGA
cohort. In general, ADVOCATE prediction aligns the best with ABSOLUTE prediction (Figure




























Figure 2.32: Compartment frac-
tion analysis of pancreatic tu-
mors from the ICGC (blue),
UNC (red), and TCGA (grey)
cohorts.




































Figure 2.33: Comparison of tissue fraction predictions by dierent algorithms, using TCGA PDA bulk.
Depicted as scatter plots by sample ID (left) and boxplots (right). Algorithms are color-coded.
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We next focused on the expression level and compartment-specicity of the genes used by each
of the three published PDA classication systems (Figure 2.34) [Bailey et al., 2016; Collisson et
al., 2011b; Mott et al., 2015]. We began by remapping the Columbia University Medical Center
(CUMC) dataset using the Ensembl GRCh37 gene annotation in order to enable comparisons to the
ICGC dataset, which uses this annotation. This resulted in 22% more genes being called than with
the NCBI annotation, and had a particularly strong impact on the many recombined immunoglob-
ulin genes that contribute to [Bailey et al., 2016] Immunogenic subtype. Notably, we observed that
the genes used to dene the Classical, Basal-like, and Progenitor subtypes were heavily weighted
towards epithelium-specic expression. Conversely, those used to dene the Activated, Normal
and Immunogenic subtypes were weighted towards the stroma. The Quasi-Mesenchymal (QM) and
Squamous gene sets were well expressed and represented a mixture of epithelial and stromal iden-
tity, consistent with a more poorly dierentiated state. Finally, the majority of genes that dene
the Exocrine and ADEX subtypes exhibited very low expression in the LCM-RNA-Seq datasets,
suggesting that their expression in bulk tissue is derived from cell types largely absent from our
microdissected samples. Together, these data provide insight into the cellular compartments that
contribute to molecular gene signatures built from bulk tumor tissue samples.
2.4.7 Transcriptional deconvolution improves outcome association of epithelial
subtypes
Having established the heterogeneity of compartment fractions across dierent PDA cohorts, we
wondered whether removing the expression contributions of stromal cells would aid classication
eorts. I used the deconvolution function of ADVOCATE to generate virtual epithelial and stro-
mal expression proles from the bulk samples of each PDA cohort (producing datasets vUNC,
vTCGA, and vICGC). In each case, the resulting virtual proles were clearly distinguished by es-
tablished cell-specic marker genes (Figure 2.35). Notably, bulk samples were distributed between
the corresponding virtual epithelium and stroma samples using both hierarchical clustering (Figure
2.36).
To address whether deconvolution improved cross-cohort consistency of molecular classiers,
we processed the virtual epithelial proles from each cohort (veUNC, veTCGA, and veICGA)























































































Collisson et al. Moffitt et al. Bailey et al.
Figure 2.34: Analysis of genes comprising three published classiers for PDA using LCM-RNA-Seq data.
Upper panel depicts the distribution of t-statistics for each of the indicated classier gene lists that were
calculated by dierential gene expression analysis between the epithelium and stroma. Positive values indi-
cate epithelial enrichment. Lower panel depicts the mean expression in log2 fragments per million mapped
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Figure 2.35: Heatmap depicts the expression of indicated marker genes in deconvolved virtual epithelial and















































































Figure 2.36: Hierarchical clustering of bulk tumors (black) and their virtual epithelial (blue) and virtual
stromal (red) derivatives for ICGC (a), UNC (b) and TCGA cohorts (c). PCA of bulk tumors (black) and
their virtual epithelial (blue) and virtual stromal (red) derivatives for ICGC (d), UNC (e) and TCGA cohorts
(f).
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Within each of the three bulk cohorts, this yielded two prominent clusters corresponding to distinct
molecular subtypes (Figure 2.37). In each case, one cluster was enriched in pathways consistent with
the Classical subtype, exhibiting aliated with exocrine pancreatic lineage, while the other was
enriched in pathways denoting poor dierentiation, including increased cell migration, invasiveness,
and angiogenesis, consistent with the Basal-like subtype. Similar results were observed when the
Mott-E classier was applied to our experimentally-derived epithelial LCM-RNA-Seq (CUMC
LCM-E) dataset (Figure 2.37b). The classication of veUNC samples aligned closely with their prior
classication from bulk proles [Mott et al., 2015] (Single Matching Coecient (SMC) = 0.84).
Moreover, application of the Mott-E classier to the veICGC dataset revealed excellent alignment
with the pancreatic progenitor and squamous subtypes described by [Bailey et al., 2016] (SMC =
0.91). The similarity among the groups of samples identied by application of the Mott-E classier
to the virtual epithelial datasets instills condence that this approach identies qualitatively similar
groups of tumors across cohorts. Of note, I found that the composition of each pancreatic tumor
cohort also varied considerably with regard to the fraction of epithelial subtype. The Basal-like
group comprised 29%, 41%, and 27% of cases in the veUNC, veICGC, and veTCGA cohorts,
respectively (Figures 2.38a-c) and 36% of our CUMC epithelial LCM-RNA-Seq proles (Figure
2.38d), further highlighting the varied composition of these collections.
Having established the identities of two epithelial subtypes in each dataset, we sought to assess
their association with survival outcomes. Of note, removing stroma-associated gene expression
with ADVOCATE improved the survival association between Classical and Basal-like tumors in all
three bulk datasets, with a particularly strong eect on TCGA outcomes (Figure 2.39) where 45%
of the samples were re-classied after deconvolution. Taken together, these results indicate that (i)
dierences in tumor composition between dierent large-scale gene expression datasets can aect
the predictive power of established classier signatures for PDA, and (ii) transcriptional deconvo-
lution can help overcome this hurdle, improving the reproducibility of outcome prediction. Thus,
ADVOCATE deconvolution may contribute to the stabilization of clinically relevant functional
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Figure 2.37: (a) Heatmap of gene expression from virtual epithelial ICGC proles that clustered into two
groups based on the expression of genes from the Mott-E classier (top 50 genes for each group shown).
Enrichment scores for indicated gene set are represented at top. Silhouette scores representing the strength
of subtype call are represented above each sample. Full names for abbreviated gene sets are available in
Table C.6. Using the same layout, epithelial LCM-RNA-Seq samples from CUMC tumors (b), UNC (c) and
TCGA (d) also cluster into two groups. Tumors with Basal-like and Classical traits, respectively, can be






















































Figure 2.38: Multilayered donut plots showing (i) the alignment of epithelial with stromal subtypes for each
tumor in each cohort, (ii) the alignment of subtypes identied in this study with the subtypes described in
earlier work for the indicated cohorts, and (iii) the proportion of each epithelial subtype. Separate pie charts
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Figure 2.39: Epithelial subtypes overall Kaplan-Meier (KM) survival analysis of patients with resected PDA
from the indicated cohorts shows that the detection of a dierential prognosis among the epithelial subtypes
is enhanced by transcriptional deconvolution across all cohorts: ICGC (a), TCGA (b), UNC (c). Thick red
and blue lines show the survival curves of tumor groups identied among deconvolved virtual epithelium
proles, while thinner light red and blue lines represent those groups detected by subtyping bulk expression
proles. Below each KM-plot, hazard ratios (HR) from a Cox proportional hazards model (CPHM) and
their 80% (blue), 90% (yellow) and 95% (orange) condence interval are compared between Basal-like and
Classical tumors as detected in virtual epithelial (ve) and bulk expression proles, respectively.
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2.4.8 Identication of Immune-rich and ECM-rich subtypes of PDA stroma
The description of tumor stroma from expression data is a rapidly-developing area, typically making
use of cell-specic marker genes or gene set enrichment to make inferences of stromal composition.
Mott and colleagues used NMF ([Lee and Seung, 1999]) on a large number of bulk PDA expres-
sion proles to develop a PDA stromal classier that identied two subtypes designated Activated
and Normal ([Mott et al., 2015]). These subtypes were interpreted to reect the biology of cancer
associated broblasts, based on the inferred contributions of activated myobroblasts versus quies-
cent pancreatic stellate cells. While this nding both aligns well with known PDA biology and was
shown to be clinically relevant with respect to outcome association, we were interested in capturing
expression signals from the stroma as a whole, including the many myeloid, lymphoid, endothelial
and other cell types that are commonly present in the PDA microenvironment. To this end, we
expanded the stromal LCM-RNA-Seq cohort described above to include samples from a total of
110 unique patients. NMF with consensus clustering identied two prominent molecular suptypes
among these samples. Clear functional identities were established for these subtypes using gene set
variance analysis (GSVA), leading to their designations as: an Immune-rich group characterized by
numerous immune and interleukin signals (Figure 2.40). We next extracted a gene signature distin-
guishing these two stromal subtypes, making use of the compartment specicity analysis described
above to lter for stroma-specic genes (see Methods and Tables C.5). Application of this signature
to the virtual stroma proles yielded two prominent groups each for the ICGC, TCGA, and UNC
cohorts (Figures 2.40). Critically, in each cohort, the two groups were again characterized by their
enrichment for gene sets associated with ECM deposition or immune processes, indicating a robust
and consistent performance of this new, stroma-specic \CUMC-S" signature.
With the exception of the ICGC cohort, no signicant survival dierences were observed between
ECM-rich and Immune-rich tumors, although trends for a worse prognosis among tumors bearing
an ECM-rich stroma became more apparent following deconvolution (Figures 2.41). As with the
epithelial compartment, the fraction of tumors in each stromal subtype varied substantially by
cohort with 62%, 52%, and 31% of samples allocated to the ECM-rich subtype for vsUNC, vsICGC,
and vsTCGA, respectively, and 47% of our stromal LCM-RNA-Seq samples (Figure 2.38d).
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Figure 2.40: Heat-maps of deconvolved virtual stromal proles from the UNC (a), ICGC (b) and TCGA (c)
cohort, respectively, as well as stromal LCM-RNA-Seq samples from CUMC tumors (d). Cluster analysis
based on the expression of genes from the ESTIMATE stromal signature produced two groups in each cohort.
Top section of heat-map depicts enrichment scores for indicated gene sets. Middle section depicts Silhouette
scores representing the strength of the subtype call for each sample. In each virtual stroma data set, two
groups were identied, one with features indicating elevated extracellular matrix deposition and remodeling
\ECM-rich", purple) and another with enriched in immune and interleukin pathways (\Immune-rich", green).
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vsICGC P = 0.0211
bICGC P = 0.014
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Figure 2.41: Kaplan-Meier (KM) survival analysis depicts overall survival relative to stromal subtype. Classi-
cations derived from bulk tumor proles are shown with thin lines while those derived from virtual stromal
derivatives are shown with thick lines. Below each KM-plot, hazard ratios (HR) from a crude Cox pro-
portional hazards model (CPHM) are shown with 80% (blue), 90% (yellow) and 95% (orange) condence
intervals (CI), comparing ECM-rich and Immune-rich tumors as detected in virtual stromal (vs) and bulk
tumor proles. Transcriptional deconvolution marginally improves outcome prediction based on stromal sub-
types, yielding a signicant dierence in outcome only in the UNC cohort when considered in a univariate
analysis.
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2.4.9 Epithelial and stromal subtypes are partially linked and associated with
survival dierences
The existence of numerous paracrine signaling pathways whose activity is aected by oncogenic
mutations implies that stromal transcriptional programs should be heavily inuenced by epithelial
identity [Laklai et al., 2016]. We examined this corollary by ascertaining the association of epithelial
and stromal subtypes in our experimental LCM dataset as well as in those from the virtual UNC,
TCGA, and ICGC datasets. We found that in the ICGC and TCGA cohorts, the ECM-rich stroma
subtype was preferentially associated with the Basal-like epithelial subtype; the UNC and CUMC
cohorts trended in this direction but did not reach signicance. However, a meta-analysis of the
393 samples from all four datasets yielded an Odds Ratio of 2.7 for the association of Basal-like
epithelium and ECM-rich stroma (Figure 2.44, random eects model:OR= 2:7 [1:33 ; 5:53], p<
0:001), indicating a partial association between epithelial and stromal compartments. Consistent
with this, combination subtypes only modestly aected the outcome prediction associated with the
epithelial subtypes alone except in the case of the UNC cohort where combination subtyping of
deconvolved samples found a particularly poor outcome for Basal-like/ECM-rich tumors relative to
Classical/Immune-rich tumors (HR = 3:76 for combined subtyping vs.2:11 for epithelial subtyping
alone).
However, same survival analysis conducted on bulk gene expression-based clustering did no pro-
vide signicant survival dierence as much as the virtual expression-based clustering as illustrated
in Figure 2.43. Especially for TCGA cohorts, no seperation was identied.
2.5 Conclusion and Discussion
The traditional understanding of genetic mutations as drivers of tumor development has led to a
focus on the malignant that is exemplied by the term "tumor purity", which regards the stroma
as mere contamination. However, with the understanding that stromal cells play critical roles in
both promoting and restraining pancreatic tumor progression [Neesse et al., 2015], the consensus
view of the stromal compartment has shifted to that of a critical partner - or foil - to the malignant
epithelium. Indeed, in some contexts the stroma can even play a dominant role, as epitomized by
the success of stroma-targeted immunotherapy in treating aggressive cancers such as metastatic
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Figure 2.42: KM survival analysis of combined epithelial and stromal subtypes in the indicated cohorts ICGC
(a), TCGA (b) UNC (c) cohort, respectively. Red lines indicate Basal-like tumors with an ECM-rich stroma
while blue lines indicate Classical tumors with an Immune-rich stroma. All other tumors are represented as a
grey line. Pie charts summarize the proportion of each category per cohort. HRs from a CPHM demonstrate
that the combined Basal-like/ECM-rich subtype is strongly associated with reduced survival in PDA patients
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Figure 2.43: KM survival analysis of combined epithelial and stromal subtypes as determined from bulk
expression proles for each of the indicated cohorts. Red and blue lines contrast Basal-like/ECM-rich tumors
against Classical/Immune-rich tumors while all other tumors are represented as a grey line. Pie charts
summarize the proportion of each category per cohort. In contrast to the combined subtyping results that
were obtained using virtual compartment-specic proles, the Basal-like/ECM-rich subtype is not associated
with a statistically reduced survival in the TCGA cohort.
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Figure 2.44: Odds ratios of Basal-
like tumors having ECM-rich stromas
across the indicated cohorts including
their 95% condence interval (upper
panel). Meta-analytic xed (FE)- and
random-eects (RE) models show sig-
nicant positive associations. Q-test
and I2-statistic indicate measures of
inter-study heterogeneity
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melanoma and non-small cell lung cancer. In this light, we sought to study the interplay of PDA
epithelium and stroma in their native state, separated by LCM from otherwise intact samples, but
matched by patient so that the reciprocal signals active in each compartment might be examined.
A key outcome of this work is to unify our understanding of molecular subtypes in pancreatic
ductal adenocarcinoma. To do this, we rst examined the properties of subtypes resulting from
existing classication schemes, making use of compartment-fraction estimation function of AD-
VOCATE as well as our annotation of the expression levels and compartment-specicity of each
gene in our LCM-RNA-Seq dataset. We noted the substantial heterogeneity of compartment frac-
tion between the ICGC, TCGA, and UNC cohorts, and detailed how certain proposed subtypes
may have emerged from variations in tissue composition. Indeed, the removal of stromal expres-
sion signals from the Mott-E signature resulted in the reclassication of nearly half the samples
and improved discernment of the functional processes associated with the Classical and Basal-like
subtypes in each cohort.
Functional similarity in subtypes is an important concept for tumor classication. It is fully
possible, even commonplace, to generate functionally distinct groups by applying the same clas-
sication signature to dierent sample cohorts. Variation in technical features such as library
preparation method or expression platform, as well as biological heterogeneity can have an out-
sized impact on sample classication systems. Thus, in our eort to establish a novel classication
system for PDA stroma, we placed the greatest emphasis on the reproducibility of molecular phe-
notypes rather than an association with overall survival. We therefore observed with great interest
the emergence of two prominent molecular subtypes in the stroma with pronounced enrichment for
two dierent aspects of stromal biology: ECM deposition and remodeling versus immune-related
processes. The dichotomy between these two functional groups emphasizes the now well-described
role that the inammatory microenvironment plays in modulating the local immune response to
PDA.
Examining both the epithelial and stromal subtypes together in combination across 393 pancre-
atic tumor specimens led to the nding that there is considerable heterogeneity in cross-compartmental
dependencies across the 393 specimens examined, with some evidence of dependence between the
global stromal transcriptional program and its epithelial counterpart. An expansive body of litera-
ture has accumulated describing myriad signaling interactions between the epithelium and stroma
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of pancreatic cancer [Bailey and Leach, 2012]. Furthermore, mutation-driven epithelial signaling
programs such as those incited by oncogenic K-ras have profound impacts on stromal cell biology
[Pylayeva-Gupta et al., 2012; Ying et al., 2012b]. However, K-ras itself is mutated in 95% of PDA
cases, so it cannot alone explain the dierences between the prominent stromal subtypes. By ex-
amining all four tumor cohorts, we found a strong association between an ECM-rich stroma and
Basal-like epithelium. The latter nding corroborates the concept that epithelial traits promot-
ing dedierentiation in PDA, such as the loss of SMAD4 expression, may in fact shape a more
matricellular and likely more, rigid stromal phenotype [Laklai et al., 2016]. This association was
less prominent in the UNC cohort and absent in our smaller group of LCM tumors. Combined
evidence from all cohorts, however, generally supports the idea of a modest cross-compartment de-
pendence. Further studies will be needed to better understand the dynamics of cross-compartment
subtypes in PDA by taking into account additional variables such as mutation status or envi-
ronmental/epidemiological factors. To this end, we provide two novel tools for the PDA eld: a
compartment-specic gene signature that may discriminate between ECM-rich and Immune-rich
stromas as well as the ADVOCATE framework which may help to assess the compartment com-
position of PDA bulk expression proles and provide virtually puried expression for downstream
analyses.
It is noteworthy that patient stratication according to both the epithelial and stromal com-
bination subtype is strongly associated with patient outcome. Specically, tumors with Basal-like
epithelium and an ECM-rich stroma have a substantially worse overall survival compared to those
with a Classical epithelium and Immune-rich stroma (HR= 3:76 [1:86 7:62]). This eect size com-
pares favorably to other known single variables in pancreatic cancer biology, including lymph node
status (HR = 1:5), postoperative CA19-9 level (HR= 3:6) or the number of high penetrance driver
genes (HR= 1:4) [Berger et al., 2008][Yachida et al., 2012] while also providing a biological context.
Unfortunately, dierences in the clinicopathological data reported for each cohort precluded a more
sophisticated mutivariate model. Nonetheless, we expect that this approach to subtyping will have
immediate applications, for example, in interpreting the results of small-scale clinical trials where
random inequalities of molecular subtypes could dramatically aect the expected survival between
groups or relative to historical controls.
The generation of virtual compartment-specic expression proles from bulk proles is a unique
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tool in the computational biology eld. Other algorithms often provide means to infer compart-
ment expression from a large group of samples based on linear modeling of putative marker gene
expression [Gill et al., 2014; Kuhn et al., 2011a], which depends on the availability of truly cell-type
specic marker genes being expressed in an essentially binary manner. By contrast, ADVOCATE
uses a Gaussian mixture approach to model the expression distribution for hundreds of genes dis-
criminating between the training conditions (i.e. epithelium and stroma). This both informs its
compartment fraction prediction function and enables the deconvolution function to be performed
on an individual-sample basis (provided appropriate reference standards for the sample are avail-
able from which scaled normalized expression may be obtained). The ADVOCATE framework may
easily be expanded to include additional compartments or cell types, given suitable experimental
data. However, it cannot generate virtual proles for any compartments that have not been sam-
pled; it can only estimate the fraction of residual gene expression that is unaccounted for by the
modelled compartments. In practice, this \Residual" compartment is inuenced both by technical
variations such as expression platform as well as biological variation such as the inclusion of non-
sampled cell types. It is therefore useful as a noise-reduction tool as exemplied in Figure 2.32.
Considering the technical challenges of performing LCM-RNA-Seq and other enrichment methods,
we expect this computational approach will reduce the need for experimental sample manipulation
in the future. Moreover, while this particular implementation was focused on pancreatic cancer,
we expect that the ADVOCATE algorithm, which requires very limited sample sizes for training,
can be generally applied to model sub-populations across the cancer eld. This will provide an
important framework for handling the cellular heterogeneity of cancer and further expanding the
utility of large-scale gene expression prole collections.
Though, deconvolution without training samples is also possible. Given a set of bulk samples,
Unsupervised learning models - i.e. factor analysis or graphical models that assuming hidden factors
as the involving compartments would be used to infer compartment specic parameters. However,
the challenge resides in interpreting biological functions of each compartment. Innovations in
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3.1 Summary
Reverse engineering approaches have been used to systematically dissect regulatory interactions
based on gene expression proles in dierent context and data types, thus improving our mechanis-
tic understanding of molecular programs under perturbations. Proteomics data, on the other hand,
provides direct evidence of cell functions. Particularly, signaling molecules are best candidates for
drug targets. Previous eorts have shown that targeting signaling proteins could potentially lead
to cancer remission. In this work, I introduce hybrid proteomics Algorithm for the Reconstruction
of Accurate Cellular Network (hpARACNE), a re-design of gene expression based ARACNE algo-
rithm. Using Clinical Proteomics Tumor Analysis Consortium (CPTAC) breast cancer proteomics
data, hpARACNE reconstructs a network that signicantly outperforms ARACNE when com-
pared with curated Kinase/Phosphatase-substrates interactions from public databases. Compared
with Stable Isotope Labeling with Amino acid in Cell Culture (SILAC) experimentally identied
substrates for EGFR, hpARACNE predicts substrates with high accuracy. Integrative network
analysis of breast cancer transcriptome and phosphoproteome reveals potential drug targets for
Triple Negative Breast Cancer (TNBC) treatment. hpARACNE has three innovations that adapt
it to proteomics data and signaling process: 1) Renement of the kinase/phosphatase peptides
by integrating matched whole proteomic and whole phosphoproteomic proles; 2) Establishment
of association based on newly designed Mutual Information (MI) estimator for missing data; 3)
Network pruning using directional Data Processing Inequality (dDPI) for signalling process.
3.2 Introduction
Protein signalling is a fundamental cellular regulatory mechanism in cells that responds to both ex-











































Figure 3.45: (a). Signalling cascade and transcriptional regulation in a cell and (b). kinases involved in
dierent tumorigenic process.
in tumorigenesis, tumor progression and replase/metastasis [Maarten Altelaar et al., 2012] (Fig-
ure 3.45a-b). Phosphorylation is one of the many types of Post-Translation-Modication (PTM)
which also includes acetylation and methylation. [Lemeer and Heck, 2009] predicts that more
than half of the proteome is regulated by phosphorylation at astonishing 500,000 sites. Protein
(de)/phosphorylation mediates signalling transduction during cell development, immune response,
transcription, apoptosis and proliferation. During signaling process, kinase and phosphatase fa-
cilitate the covalent conformational modication of substrates, and change their activities. The
promiscuity of kinases and phosphatases could be seen as a natural mechanism to tune protein
function. Aberrant regulation of kinases plays a causal role in many diseases, thus making kianse
proteins top desirable drug targets. In human cancers, the inter-connected kinase/phosphatase
tuning process constitutes a complex protein signalling network that is critical for carcinogenesis
or tumor metastasis [Maarten Altelaar et al., 2012].
3.2.1 A brief history of kinase inhibitor development
Imatinib (Gleevec, [Iqbal and Iqbal, 2014]), a kinase inhibitor targeting Bcr-Abl tyrosine kinase
domain, rst eectively treated Chronic Myelogenous Leukemia (CML) patients and brought re-
mission with an 95% 5-year survival. This work pioneered precision medicine targeting kinases
in cancer research. The maturation of high throughput proteome quantications later fueled the
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fast development of a collection of kinase inhibitors. Sorafenib [Abou-Alfa et al., 2006] then eec-
tively cured VEGF and b-Raf activated Hepatocellular Cancer (HCC) by inhibiting the Raf kinases
domain. [Wilhelm et al., 2008] and [Wilhelm et al., 2008; Llovet et al., 2008] then showed that
the same drug also ceased Vascular Endothelial Growth Factor Receptors (VEGFRs) activity and
Platelet-Derived Growth Factor Receptor beta (PDGFR-) activity, respectively, thus increasing
survivals of specic lung cancer patients. Sunitinib [Demetri et al., 2006] was soon approved to
treat both Renal cell carcinoma (RCC) and gastrointestinal stromal tumor, targeting c-KIT/RET
kianse protein. Vemurafenib [Bollag et al., 2010] later was developed to specically target B-RAF
V600E mutation in late-stage melanoma. [Blackwell et al., 2010] discovered another tyrosine ki-
nase inhibitor - lapatinib - targeting HER2, treating breast cancer, the most prevalent cancer type.
[Calcagno et al., 2016; Wang and Lockhart, 2012] then reproted that Regorafenib and Aibercept
combined treatment improved progression-free survival for metastatic colorectal cancer patients,
by inhibiting multiple tyrosine kinases and VEGFR. Many additional inhibitors were then devel-
oped: Crizotinib targeting ALK; Getinib and Erlotinib targeting EGFR [Maemondo et al., 2010;
Gridelli et al., 2007]. These kinase inhibitors, particularly tyrosine kinase inhibitors, have eectively
treated various cancer types, primary or metastasis.
However, cancer patients developed resistance to targeted therapy: Lung cancer patients with
ALK rearrangement became immune to crizotinib [Casaluce et al., 2016] just six years after being
eective treated; those with EGFR-mutant developed resistance to getinib [Chen and Fu, 2011].
Many factors could contribute to the resistance. Cancer stem cell theory hypothesized that left-over
hematopoiteic tumor stem cells from chemotherapy lead to relapse [Dean et al., 2005]. [Gottesman,
2002] believed that resistance was arised from the treatment. Alternatively, resistance to handful
drugs might be caused by other mechanisms such as selective loss of clonal responding to some
targeted drugs, specic metabolism of a drug, discriminatory loss of cell surface transporter for a
drug. In such cases, using multiple drugs that entry into the cells with dierent mechanism or target
dierent cellular components achieves higher cure rates and could even prevent drug resistance
[Gottesman, 2002]. Intuitively, a tumor could escape form one compound, but it is improbable
to resist to multiple drugs simultaneously. In practice, patitents treated by poly-therapy survives
signicantly longer than that by single-agent therapy in metastatic breast cancer [Miles et al., 2002].
Mechanistically, the mode of action (MOA) for these poly-therapy dependent not only on MOA
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Figure 3.46: Mass Spectrometry Con-
cept
Peptides were ionized before going
through the magnet eld, followed by
a detector and amplifers for detection
of peptides of dierent m/q ratios.
Figure adapted from Wikipedia.
of each drugs, but also on interactions among their targets. Thus, elucidation of the underlying
dynamic signalling network is both critical and essential to systematically understand and discover
candidate combination/poly-therapy options.
3.2.2 Introduction to mass spectrometry
So far, The most widely used technology to quantify proteins is Mass Spectrometry (MS), rst
established 100 years ago to measure protein peptide by its mass-to-charge ratio. In general, three
parts features a mass-spec (MS): 1).An ion source; 2).A mass analyzer; 3).A detector, Figure.3.46.
Briey, classical MS machine starts with a source sample, i.e. peptide fragments. An ionizer then
converts them into ionized peptides (ion for short) that are later extracted from the sample and
then sent to an analyzer that distinguishes fragments by mass-to-charge ratio (m/z). A detector
at last measures the m/z that represents abundances of detected ion. In modern bottom-up high
throughput proteomics, input samples are prepared in dierent ways, and then coupled with various
detection techniques and computational methods to calibrate peptides m/z. Modern proteomics
technologies, particularly MS-based protein identication, have better automated equipment, var-
ious sample preparation techniques and high resoluted detector. In particularly, various labeling
approaches can multiplex up to 10 samples in one run, powered with high resolution detectors,
this signicantly increases the whole proteome quantication capacity (Figure.3.47). In general,
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Figure 3.47: MS/MS Sample preparation techniques including 1) Label-free method; 2)SILAC; and 3) Multi-
plexing
peptides from one sample and the labelled approach extracting only targeted peptides, or labelled
method, for which peptides barcoded with sample identities are mixed to run in one MS then later
de-multiplexed from MS chromatography, representing relative/absolute abundance of peptides for
individual samples. Based on chemicals and multiplexing throughput, there are three major la-
belling approaches (Figure 3.47): i). Stable Isotope Labelling with Amino acids in Cell culture
(SILAC, [Mann, 2006]) uses a cell culture system to incorporate a pair of light-chain and heavy
chain labelled samples into one MS run; ii). Isobaric Tag for Relative and Absolute quantitation
(iTRAQ, [Ross et al., 2004]) uses chemical with distinctive and separateable weights to tag ei-
ther four or eight sample a prior ; iii). Tandem Mass Tag (TMT, [Thompson et al., 2003]) could
now multiplex two, six [Dayon et al., 2008] or ten samples [Werner et al., 2014] in one MS run.
Control samples are usually included in multiplexing to normalize relative peptides quantity thus
cross-sample comparisons are legit. A special protein extraction protocol could be added a prior
to enrich targeted proteins, such as phosphoproteins, membrane proteins, or organelles proteins.
Thus we can have funcitonal/cellular specic information. [Tan and Martinez Arias, 2006].
The Clinical Proteomics Tumor Analysis Consortium (CPTAC) generated several types of
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proteomics dataset, including glycoproteomic, whole proteomics and phosphoproteomics. It used
clinical samples from TCGA cancers patients including breast invasive carcinoma, ovarian cancer,
and colorectal adenocarcinoma [Whiteaker et al., 2014]. CPTAC repository, so far, represents the
largest whole proteomics dataset from clinical samples. This high quality and large-scale data
permits comprehensively investigation and systematical modelling of cancer signalling activities.
[Zhang et al., 2014] rst used this data to integrate genomics and proteomics of colon and rectal
cancer samples, revealed the inconsistency between mRNA and protein eects for Copy Number
Variants (CNV). This work also extended the functional interpretation of genomics into proteomics.
[Zhang et al., 2016] later successfully linked genomics rearrangements with proteomics information
in ovarian cancer, discovered the genomic convergence on signalling pathways. [Mertins et al., 2016]
soon connected somatic mutations with protein though network-based method in breast cancer
samples. When connecting genomics with functional proteomics, many such molecule mechanism
were discovered and clinically meaningful conclusions were made, shedding lights on potential
application in practice.
3.2.3 Signalling network reconstruction
Global signalling network reconstruction started prospering from late 1990s after coupling compu-
tational simulation with systems biology theory development. For example, [Spiro et al., 1997] rst
elucidated signalling transduction in bacteria based on mass action kinetics and Michaelis-Menten
kinetics model, precluding large-scale signalling network reconstruction in dierent organism and
at dierent scale. [Weng et al., 1999] later explained the complexity of biological signalling systems,
pointing out both the needs of experimental data generation and proper simplication of system to
successfully implement network reverse engineering. [Ideker et al., 2001] soon successfully recon-
structed yeast genetic-signalling network, summarized systems biology approaches in deciphering
the complicated signalling network. Various large-scale signalling reconstruction methods used
dierent mathematical and statistical methods based on massive high-throughput data became
avaialbe last decades. Four statistical inference methods are widely used: 1) Correlation based; 2)
Dierential equations based; 3) Bayesian inference; and 4) Information theoretic based [Le Novere,
2015] (Figure.3.48).
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Figure 3.48: Methods for measuring associations include 1) correlations for linear regression based methods;
2) Ordinary Dierentially Equation based methods; 3) Bayesian Inference based methods and 4) Information
theory based methods.
reaction in signalling process, [Eungdamrong and Iyengar, 2004] applies this concept and then
identied the optimized solutions for system parameters. Alternatively, Bayesians uses curated
signalling pathways as prior knowledge, with protein perturbation data, and then infers posterior
signalling networks [Sachs et al., 2005; Mukherjee and Speed, 2008; Ciaccio et al., 2010; Hill et
al., 2012]. Lastly, information theory views signalling cascades as information ows, a notation in
signal process, to infer network topology [Rhee et al., 2012]. Specically, ARACNE uses Mutual
information to measure genes associations based on gene expression data [Margolin et al., 2006], thus
reverse engineers global mammalian regulatory network, which is then used to analysis pathways
mechanisms.
3.2.4 Signalling network reconstruction based on proteomics data
Despite of accumulation of proteomics data and prosperity of signalling network reconstructions,
challenges from either technical factors, such as data quality, or biological complexities, including
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the delicate stoichiometry and intricate binding of signalling proteins, are still present.
mRNA sequencing was made possible by using Polymerase Chain Reaction (PCR) to amplify
input mRNAs to a sucient amount for high throughput sequencing. Whereas, proteins can
not be amplicated, thus limits its high throughput quantication. The transient and dynamic
nature of protein futher exacerbates the diculty in quantifying functional proteins. In addition
to experimental challenges, proteins, especially signaling proteins, have intrinsic properties that
restrains its large-sclae quantication. One of these intrinsic diculties is the proteome complexity
that is driven up by many biological processes such as RNA alternative splicing, non-coding RNA
regulation and post-translational modications [Weng et al., 1999; Azeloglu and Iyengar, 2015]. In
cancers, the intricacy is further convoluted by aberrant genomic or epigenomic events occuring in
carcinogenesis process.
Current whole proteomics/phosphoproteomics data presents many challenges.[HERE] Dierent
from mRNA expression data, MS-based proteomics data is of higher sparsity, with presence of vast
missing data, with manifold protein species (higher dimension) but smaller sample size, resulting
in a decreased signal to noise ratio. Plus, well documented annotation for genes is replaced with in-
completely and unstructured glossaries for various protein species such as PTM-modied, organelle
specic, or tissue-specic proteins. Set aside individual molecule, the interactions among them are
also quite distinct for signalling. Dierent from unidirectional TF-target regulation, signals passed
by kinases always activate its substrates by adding phosphate to it, while phosphatase always deac-
tivate the substrates by removing phosphate. Depending on specic context, these reaction could
act as a switch-like gate controller in one case, or be dependent on protein abundance in another
scenario. Thus, proper modeling of signalling process has to consider those biological functions
which are not present in other network reconstruct models. Taking together, those uniqueness of
proteomics data and signalling process calls for methods that can process information in the data
regardless of the noise, that can model model signalling network but still recognize the intrinsic
biological complexity.
3.2.5 Introduction to ARACNE
Algorithm for Reconstruction of Accurate Cellular Network (ARACNE) [Margolin et al., 2006]
uses Mutual Information (MI) to identify regulatory relationship between Transcription factors
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(TF) and targets using gene expression proles. There are ve major components in ARACNE:
1).Data normalization and transformation; 2) Association computation using MI; 3) Candidate
network; 4) Network pruning based on Data Processing Inequality; 5) Final network assembly
(Figure 3.49). Among them, step (2) ensures representation of association from the input data,
and step (4) warrants increased number of direct biological regulations between TFs and targets.
This systematic dissection of regulatory interactions in dierent context improves our mechanistic
understanding of intricate regulatory curcuit in human B cells [Basso et al., 2005], for pheno-
typical transition in brain tumors [Carro et al., 2009], and major neurodegenerative factors in
parkinson's disease [Brichta et al., 2015]. All those studies illustrated mRNA level explanation
of some molecule mechanisms. However, system-wide analyses of the direct functional molecule,
in particular phospho-proteins, were still severely hampered by the lack of appropriate analytic
programs, which were currently gene-centric and did not accommodate the global level analysis
of Post Translational Modications (PTMs) on proteins. As of now, there were lots of protein
signalling networks which were either curated from literature thus far from complete, or inferred
from gene expression proles thus very noisy. As mRNA expression is usually followed by biological
processes such as RNA alternative splicing, post-translational modications, and non-coding RNA
regulations, which changes the consistence between mRNA expression and Protein activity, thus
confounding the direct inference from mRNA expression to protein interaction.
3.2.6 Introduction to hpARACNE
Applying ARACNE directly to proteomics data is not appropriate. Here, I introduce hybrid
proteomic Algorithm for the Reconstruction of Accurate Cellular Network (hpARACNE), an ex-
tension of the ARACNE algorithm, to dissect signalling networks using high-throughput proteomics
data. While ARACNE takes Transcription Factors (TF) as regulators that targets DNA sequence,
gene expression data as quantication, hpARACNE uses kinases or phosphatases as regulators
thats de/phosphorylates substrates, proteomics data as quantication. hpARACNE rst rene
noisy quantication of regulatory proteins integrating phospho-peptide abundance and the cog-
nate whole protein abundance. Then it associates protein regulator and substrates using Mutual
Information (MI) which was newly devised to calculate MI for sparse data with missing values. It
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Figure 3.49: ARACNE algorithm has three major components a) data preparation and association calcu-
lation using Mutual Information, b) network pruning based on Data Processing Inequality and c) network




















Figure 3.50: hpARACNE framework outline. iTRAQ phosphoproteome and global proteome LC-MS/MS
proles are used to rst calculate association and conditional association between phosphoprotein and global
protein for each protein in matched matter. Mutual Information is calculated for all possible enzyme and
substrate using phosphoproteome quantication. A matched null model is used to identify informative pairs.
directed DPI process is then applied to detect directly action pairs. Finally, 100 bootstrapped network are
consolidated, together with modulator network in step 2, generating a nal signaling network. Numbers
indicate steps described in main text.
prune network. Using Clinical Proteomics Tumor Analysis Consortium (CPTAC) breast cancer
proteomics data, hpARACNE network achieves at least four times higher recall than ARACNE
network for the same precision. EGFR substrates predicted by hpARACNE are then validated
using public breast cancer SILAC experiments and curated substrates from databases. Analyz-
ing breast cancer transcriptome and phosphoproteome together reveals potential drug targets for









3.3.1.1 Breast Cancer Dataset Proteomics and Phosphoproteomic data
The abundance of all peptides with phosphotyrosine (pY), phosphoserine (pS), or phosphothreonine
sites (pT), - phosphoproteomics data (PP), was obtained by high-resolution accurate-mass tandem
mass spectrometry (MS/MS). It includes 36 isobaric Tag for Relative and Accurate Quantication
(iTRAQ 4-plex) experiments of a total of 108 human breast cancer samples (subset of TCGA cancer
sample) from Clinical Proteomic Tumor Analysis Consortium Components data portal (CPTAC,
[Whiteaker et al., 2014]) following a strategy illustrated in Figure 3.51.
Meanwhile, a matched set of global whole proteomics (WP) representing the cognate whole
proteins abundance was obtained following the same iTRAQ 4-plex design. The proled cohort
includes a balanced representation of PAM50-dened [Chia et al., 2012] breast cancer intrinsic
95
subtypes: basal-like (n=25), luminal A (n=29), luminal B (n=33), and HER2 (ERBB2)-enriched
tumours (n=18). Additionally, 3 normal breast tissue samples were included; 3 tumor samples were
replicated. The 4-plex iTRAQ design designates 3 channels for tumour samples and a 4th common
internal reference sample that is comprised of 40 individual tumours of the above-mentioned sub-
types, 10 for each. Using this design, a total of 36 runs by this iTRAQ MS/MS spectrum measures
peptide abundance for a total of 108 breast cancer samples. (Figure 3.51).
3.3.1.2 Data preprocessing
Each of the 36 PP PSM dataset was parsed following criteria stated in CPTAC documentation: 1)
Keeping only pS/pT/pY containing peptides; 2) Keeping peptides with reported phosphor-peptide
probability score > 99, meaning a localized phosphor-site; 3) Keeping peptides with iTRAQ score
< 0:5, meaning condent call for reporter ion signal in MS2; 4) Assigning 0 to peptides with
problematic peak nding; 5) Removing peptides with control channel (117) signal = 0 ; 6) Taking
maximum if one peptide presents in multiple segmental les within one run; 7) Annotating peptides
with phosphorylation location and type; 8) Annotating peptides with protein identication. After
cleansing, phosphopeptide reportor ion abudance was further normalized following method used by
[Zhang et al., 2014] to produce relative abundance ratio of phosphopeptides comparing to control
sample. Briey, to standardize iTRAQ reporter ion intensity for each peptide, each signal was
compared to the reference channel at rst, and then median normalized. Specically, median log2
ratio between sample channel signal (114, 115, 116) and control channel signal (117) was taken as
a normalization factor Fn. By multiplying this Fn to the original log 2 ratio, the normalized signal
was calculated (Equation 3.39). After normalization, the medians of samples from one 4-plex run
were all centered at 0 (Figure 3.52). Finally, All 36 datasets were merged, resulting in a dataset of




































































Figure 3.52: Exmaple of
peptides ratios before (left)
and after (right) meidan
normalization.
3.3.2 Public SILAC datasets
EGFR SILAC (Stable Isotope Labeling with Amino acid in Cell Culture) experiment in KPL-4
breast cancer cell line was performed by treating the cell line with 5m erlotinib for 5, 10, 30, 60
minutes after 24 hours serum starvation. Three independent biological replicates were prepared at
one-week intervals following the same procedure. More details about the experiments can be found
in [Tzouros et al., 2013]. I merged all 5 treated samples to identify signicantly decreased proteins as
candidate EGFR substrates after normalization following original study (adjusted p-value <0.05).
SYK SILAC experiment was performed in three dierent breast cancer cell lines: MCF7,
MCF7/ADR, and MDA-MB-231 by treating MCF7 with Syk inhibitor piceatannol and the other
two with known SYK kinase activators. More details about the experimental procedures can be
found in [Larive et al., 2009]. In this analysis, I combined the decreased proteins in SYK inhibited
MCF7 cell lines (cuto=1.1) and increased proteins (cuto=1.3) in both MCF7/ADR and MDA-
MB-231 cell lines as candidates SYK substrates following the criterias reported in the original study
by [Larive et al., 2009].
PI4KII and EGFR dual inhibition SILAC experiment was performed by treating MDA-MB-
231 breast cancer cell line using AG1478, a EGFR inhibitor and PI4KII knockdown. The dual
inhibition SILAC was compared to PI4KII knock down SILAC experiment. For both experiments,
cell lines were EGF stimulated for 10 mins before treatment. In this analysis, PI4KII substrates
were identied by comparing to a null control, the light chain [Li et al., 2014].
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3.3.3 Curated signalling network.
A knowledge-based kinase-substrates signalling network was curated from four dierent public
database: 1) Human Protein Reference Database (n=5158, [Peri et al., 2004]) (http://hprd.org/
download); 2) phosphoELM (n=2462, [Diella et al., 2004]) (http://phospho.elm.eu.org/); 3)
phosphoSitePlus (n=4597, [Hornbeck et al., 2012] (http://www.phosphosite.org/staticDownloads.
action); 4) DEPOD (n=XXX, [Duan et al., 2015]) (http://www.koehn.embl.de/depod/download.
php). A total of 334 regulatory enzymes, including 221 kinase and 113 phosphatase, was connected
to 3303 substrates, constituting a signalling network of 7915 edges.
Precision-recall curves were computed using this curated signalling network as gold standard
network (GSN, Equations 3.40). Each point on the curve represents one copmarison when taking
a maximum p-value to cut the edges in the predicted network when compared with the GSN. I
observed that the well-studied hub regulators in GSN were connected to the majority of observed
substrates than that of under-studied kinase/phosphatase, a phenominon known as knowledge-bias,
thus penalizing the algorithms' capacity of predicting substrates for under-studied regulators. To
account for this unfairness, a second type of curve was computed by sub-selecting regulators with









3.3.4 Kinase and phosphatase list
Human kinases (n=538, [Cheng et al., 2014]) together with active human phosphatase (n=238)
from DEPOD database [Duan et al., 2015] were used as the enzymatic regulators in constructing
human signalling network in this study. In the CPTAC Breast cancer PP dataset, 391 out of the
538 kinases were mapped to 5704 kinase peptides with pS/pT sites, the remaining 108 Tyrosine
kinases were mapped to 290 kinase peptides containing pY sites; 145 out of the 238 phosphatase
were mapped to 1563 peptides.
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3.3.5 Hybrid proteomics ARACNE algorithm
ARACNE is originally designed to use gene expression data which is continuous and non-sparse,
with 20,000 genes and hundreds of samples. However, the CPTAC iTRAQ phosphoproteomics
data does not have those nice properties. Instead, it is very sparse and has signicant number
of missing data, encoding information that represents kinase activation, phosphatase deactivation,
etc. Those disparities make directly application of ARACNE in reverse engineering signalling
network from proteomics data not appropriate. To deal with the specic technical challenges in
such proteomics data and to accommodate biological relevance involved, specically to investigate
the global signalling patterns in breast cancer phosphorylation here, I designed hybrid proteomics
ARACNE (hpARACNE), as an renovated version of ARACNE. Next, I introduce the major
innovations in hpARACNE in detail: input ltering, mutual information calculation, and data
processing inequality.
3.3.5.1 Peptide renement
Intuitively, the phosphorylation of a protein (PP1) required the presence of a bait protein (whole
protein), when above certain stoichiometry, one could expect modest association between abun-
dance of PP and its cognate WP1. Based on this assumption, phosphopeptide (PP1) that has
signicant association with its cognate WP1 was regarded as condently quantied phosphopep-
tide (Spearmans Correlation test). However, in some cases this association could only be observed
with the presence of a second PP (PP2), a phenomenon called modulation by PP2. In such cases,
conditional association of PP1 and its cognate WP1 given PP2 could be computed using conditional
mutual information (CMI) [Wang et al., 2009; Giorgi et al., 2014]. However, calculation of CMI
requires large samples size. Herein, constrained by the sample size, I used partial correlation in-
stead to calculate this conditional association between PP1 and WP1 given PP2 following the same
schema described by [Martnez et al., 2012] (Equations 3.41). Briey, after ranking samples by PP2
abundance, Spearman Correlations test were calculated for the samples in the two extreme tails
respectively (L+WPe , L
 
WPe
, tail size 5). Then, Fisher0s transformation was used to transform the
two p-values into a z-score, from which a p-value was then computed based on this z-score as the
condence level for the conditional association (Equations 3.41). Theoretically, if the correlations
















Figure 3.53: Phosphopeptides renement using (a) Mutual infomration between Kinase and subtrates (Top,
Equation 3.41a.) and Conditional Mutual Information (CMI) conditioning on global whole protein abun-
dance (Bottom, Equation 3.41bcd.). (b). A network generated by CMI calculation. each node is one
enzymatic peptide
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imposed by PP2. Likewise, a bigger dierence between the tail correlations would mean a higher










I = I[PPe;PPsjWPe 2 L+WPe ]  I[PPe;PPsjWPe 2 L WPe ] 6= 0 (3.41b)







Finally, a Bonferroni correction was applied to adjust multiple hypothesis testing before thresh-
olding using maximum p-value= 0:05 to eliminate noisy peptides. As a spino from the conditional
association calculation, modulating interactions between phosphopeptides were revealed, constitut-
ing a densely interconnected kinase/phosphatase-kinase/phosphatase peptides interaction network
(Figure 3.53b). In my data, matched pT/pS or pY phosphorylation type is required for renement
process to accommodate chemical reaction property: pT/pS interacts with pT/pS, and pY interacts
with pY.
3.3.5.2 Estimation of mutual information using hybrid adaptive partitioning.
Traditionally, MI between two categorical variables could be computed using contingency tables.
For continuous variables, this calculation requires proper approximation, usually taking dierent
ways of discretization or binning strategy such as the adaptive partitioning approach in ARACNE
[Lachmann et al., 2016] (Figure 3.54a). It does so by rst rank transforming variables, and then
equally splitting the 2-D space into four quadrants at the median points of each dimension. This
splitting produces a rst binning, from which a rst intermediate MI will be calculated. Following
this exact splitting and intermediate MI computing schema, the estimation goes recursively until
no more than four data points are left in a sub-quadrant or the next splitting provides no signicant
dierence among the sub-quadrants based on Chi-square test (p-value= 0:05). After summing up all
intermediate MIs and proper normalization, MI of a given pair of variables was estimated [Lachmann
et al., 2016; He et al., 2017]. This non-parametric approximation approach is computational ecient
and fast as it requires no extra eort to tune optimal number of bins or estimate proper bandwidth



















Proteomics Data with Missing Value
(b)
Figure 3.54: Mutual Information (MI) Estimation for dierent data types: In ARACNE (a), based on Gene
Expression Data represented by mRNA expression, a equally splitting adaptive partitioning strategy is used
to calculate MI, along with a null model where MIs are computed between randomly permutated variables.
In hpARACNE (b), based on sparse phosphoproteomic data with vast missing values (NA), a hybrid splitting
partitioning strategy is used to estimate MI, accompanied by a null model where permutations were done
by retaining data sparsity (keeping NA size, shaded sections) of variables.
However,when there are signicant missing values presents, equal partitioning might end up
articially splitting missing values into dierent sub-quadrants, imposing dierent meaning to them,
resulting in a biased MI estimation. Intuitively, no more information should be added or removed
from the input data when doing computation, even when there are missing values. This is exactly
what hpARACNE innovated about. Instead of blindly ranking all data points and equally splitting,
it rst tabulates all missing values into three quadrants, equally sized or not, the fourth quadrants
is designated to all data points without missing value. This rst partitioning provides the rst
intermediate MI in hpARACNE MI calculation (Figure 3.54b). The recursive partitions continuous
in the fourth quadrants using ARACNE adaptive partitioning. Finally, a similar summation and
normalization process were applied to compute MI for two random variables with missing values
present.
To approximate the statistically signicance of one association based on MI, ARACNE randomly
permutes ranks of random variables, assuming that a MI that is signicant higher than a random one
implicates a condent association. If hpARACNE sticks to this model, it is going to under-estimate
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the background noise encoded in the sparse input data. Thus, it permutes data by retaining missing
value size in the data, building up the background MI distribution for hpARACNE (Figure 3.54b).
3.3.5.3 Directional Data Processing Inequality (dDPI)
After nishing MI computation, a candidate network will be generated representing all potential
biological connections in the data. Among them, many might be false positives without biological
relevance. ARACNE uses DPI to prune the candidate network to further reduce the noise in the
network (Figure 3.55a). DPI is a information theory property with markovity, stating that infor-
mation can only be lost in transduction within channels. This markovity of DPI is particularly
useful in removing indirect associations between TF and targets, producing a sparse TF regulatory
network. In signalling cascade, information ow is channelled by chemical reactions: with kinases
adding phosphate groups to their substrates, positively correlated with them; phosphatases remov-
ing phosphates from active substrates, negatively correlated with them. Clearly, each of the up
and down directionality of signalling interaction is thus constrained by its upstream enzymatic reg-
ulator: + for kinases, and - for phosphatase. hpARACNE imposes a direction for each interaction
according to its enzymatic regulator property (directional DPI or dDPI).
Specically, for two types of enzymatic regulators, there could be four dierent types of tri-
anglar modules (Figure 3.55b): i) In the case of kinase-kinase-substrates triangle, every connections
in it must have positive correlations for dDPI to remove indirect regulations; ii) A phosphatase-
phosphatase-substrates triangle should have negative correlations for each connection, but compar-
ing a doulbe negative eect with a single negative does not obey the rule for dDPI, thus dDPI is
not applicable; iii) dDPI is also not applicable when comparing kinase-phosphatase-substrate down
regulation eect with kinase-substrate up regulation eect; iv) Comparing phosphatase-kinase-
substrate down regulation eect with phosphatase-substrate down regulation again would help to
remove indirect down regulations of substrates, thus dDPI is applicable (Figure 3.55).
3.3.5.4 Consolidation of signalling networks.
Similar to ARACNE, to decrease potential impacts from outlier samples in input data, multiple
bootstrapping (n=100, random sampling with replacement) were done to build networks which










Figure 3.55: Data Processing
Inequality (DPI) without di-
rectionality used in ARACNE
(a) among TF-TF-target trian-
gle and directed DPI (dDPI)
used in hpARACNE (b) among
enzyme-enzyme-substrate trian-
gle constrained by enzyme func-
tions either as a kinase (activa-
tion) or as a phosphatase (deac-
tivation).
edge from all bootstrapping networks. Only edges with a p-value < 0:05 were output in the nal
assembled network.
3.3.6 Simulation
Random dataset with missing values were generated based on Gaussian distribution with mean= 0
and standard deviation follows uniform distribution from [1; 5], and then randomly assigning missing
values to a given number of data points (total data points for each variableN = 100, varying number
of missing value NNA = 30%; 50%; 70%). A matrix (X) with intrinstic correlation was generated
by initializing a covariance matrix  with a preset correlation (Rho = 0:7) and then following
a multi-dimension Gaussian distribution (mvnorm function in R). A binary matrix was initiated
using the same covariance matrix, but following multidimensional binomial distribution (rmvbin
function in R). And then overlaying this binary matrix onto the X to produce a dataset with
intristic correlation and missing values.
For all comparisons in this work, missing values in the above two simulated datasets were then
imputed based on Gaussian distribution based on the mean and variance of each variable.
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3.3.7 CPTAC hpARACNE network
As of the specicity of pS/pT and pY, the input dataset was separated into pS/pT sub-dataset and
pY sub-dataset after the renement step. Then, signalling networks were reconstructed for each
sub-dataset, respectively with pre-set maximum p-values to call signicant MI (10 7 for pS/pT,
and 10 4 for pY). Combining these two networks, together with the network generated by condi-
tional association in step 3.3.5.1 by CMI, the nal signalling network was constructed, with each
node representing one phosphorpeptide, each edge representing one signalling reaction. Mapping
those peptides to protein ID generates a signalling network between kianses/phosphatase and their
substrates.
3.3.8 Network analysis
The R package VIPER [Alvarez et al., 2016a] was used to perform network-based analysis for
both gene expression proles (mrnaVIPER) and the phosphoproteoin quantication proles (phos-
pVIPER) of CPTAC breast cancer patients (n= 105). When running mrnaVIPER, an ARACNE
regulatory network constructed from all TCGA breast cancer patients were used to compute ac-
tivities of master regulators using 105 expression proles, by taking sample means as the control
group. For phosphoprotein analysis, hpARACNE constructed signalling network, together with
105 phosphoprotein abundance proles was used to calculate virtual activities of enzymes using
VIPER (phospVIPER).
Subtype-specic activated/de-activated enzymes were identied using student t-test between
dierent PAM50 subtypes for all kinases/phosphatases which were also represented in mrnaVIPER
(n=145). Among them, those with an FDR adjusted maximum p-value of 0.05 for both mrnaVIPER
and phospVIPER were identied as consistently activated/deactivated enzymes also regulating
mRNA expression.
3.4 Results
3.4.1 Overview of hpARACNE algorithm
Phosphorylation of kinase substrates is usually determined by the phosphorylation state and level of
the cognate upstream kinase. Likewise, dephosphorylation of phosphatase substrate is determined
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by the phosphorylation state and level of phosphatase. Therefore, an association between the
phosphorylation level of kinase/phosphatase and its cognate substrates must be observed when their
phosphorylation levels are measured over a compendium of samples. Here, I present hpARACNE,
a novel algorithm that is precisely designed to measure this association, resulting in an inference of
novel substrates of kinases/phosphatases. hpARACNE is based on an existing and highly successful
algorithm called ARACNE that applies information theorey on compendium of gene expression
proles to infer interactions between transcription factor and its targets [Margolin et al., 2006;
Floratos et al., 2010; Lachmann et al., 2016; He et al., 2017]. ARACNE inferred TF targets across
multiple cellular contexts with experimental are validated wiht an accuracy of over 80% [Basso et
al., 2005; Carro et al., 2009; Basso et al., 2010; Della Gatta et al., 2012; Sonabend et al., 2014].
3.4.1.1 CPTAC proteomics dataset
The Clinical Proteomic Tumor Analysis Consortium (CPTAC) quanties whole proteome and phos-
phoproteome by comparing each peptides abundance with that from the internal reference average
sample, a multiplexing technique known as iTRAQ enriched Liquid chromatography-mass spec-
trometry (LC-MS/MS). CPTAC proles 108 breast cancer patients including 25 Basal-like/Triple
Negative Breast Cancer (TNBC) samples, 18 HER2-enriched and 62 Luminal A/B patient samples.
It identies a total of 102; 886 phosphopeptides, including the peptides with phosphoserine (pS),
phosphothreonine (pT), and phosphotyrosine (pY), that are mapped to  10; 872 unique proteins.
Among all phosphopeptides with enzymatic functions according to public databases, there are 5704
pS/pT and 290 pY peptides, corresponding to 397 proteins (out of 538) and 145 phosphatase protein
(out of 238).
The relative abundance of phosphorylation types (pS, pT, and pY) has a known distribution
with majority of them having pS/pT sites and a small fraction of pY phosphorylated peptides. In
this data,  90% of detected phosphorylation are pS/pT single or double phosphorylation, < 5%
of them are pY phorphorylated, corresponding to  24000,  4000,  1500 unique pS, pT and
pY phosphorylation sites (Figure 3.56a-b). This is consistent with reported proportions among
dierent types of phosphorylations.
To sum up, the whole phosphoproteome quantication measures a large number of phosphopep-
tides, but it is sparse. 50% samples (n=105) have > 20% missing value. When taking 10 samples
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Figure 3.56: CPTAC Breast Cancer iTRAQ phosphoproteomics data. (d) illustrates the data sparsity. Num-
ber of detected peptides (x-axis) drops with increased samples size (y-axis). (a) missing values proportion
decreases greatly with increased samples size. (a) shows data quality. No detection bias for peptide with
specic phosphorylation type. (b) shows the number of detected phosphorylation sites in data
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( 10%), the data only has values for half of the measurements. That is only  20; 000(< 20%)
phosphopeptides with > 50% quantication for all samples (Figure 3.56c-d). The matched global
whole proteomics data measures abundance of 14708 proteins, 8666 of them have corresponding
phosphoprotein detected in at least 3 samples.
3.4.1.2 hpARACNE framework
Two specic properties of ARACNE limit its direct application on the CPTAC proteomics data.
ARACNE rst requires the input data to be non-sparse, a property of the data that is lacked in this
whole genome phosphoproteomics data. The phosphoproteomics data is not only sparse, challenging
correct calculation of Mututal Information (MI), but also of high complexity - more phosphopeptides
and smaller sample size comparing to transcriptomic data . Secondly, ARACNE infers undirected
regulatory network. But directionality is an inherent to kinase/phosphatase signaling process where
kinase is usually positively correlated with its substrates and phosphatase negatively associated
with its substrates. hpARACNE deals with these two aspects by renovating all key components of
ARACNE algorithm (Figure 3.50). To handle increased noise-to-signal ratio in phosphoproteomics
data, it uses matched global whole proteomics and phosphoproteomics quantication to lter low
quality phosphopeptides. To handle parsity and missing value, it crafts hybrid adaptive partition
to compute mutual information (hpMI), accommodating by a new null model to reveal hpMI
statistical signicance. This schema replaces the kernel density estimation and equal partitioning
used by other ARACNE versions [Margolin et al., 2006; Floratos et al., 2010; Lachmann et al.,
2016]. To account for signaling biology, it imposes directionality to the DPI process, reducing false
discovered edges in the nal network. Following, I am going to introduce these innovations in
details.
Enzymatic peptides renement using matched whole proteome and phosphoproteome
Here, I call all the kinase phosphopeptide and phosphatase phosphopeptide as enzymatic phos-
phopeptides, or enzymatic PPT. The quality of these enzymatic PPT quantication is critical to
the accuracy of network prediction. Any noise in their measurements will be 100,000 times ampli-
ed when computing MI with their possible substrates. Thus, hpARACNE rst renes the list of















Figure 3.57: hpARACNE re-
nement eliminates lower qual-
ity enzymatic PPTs. MIs related
to kept-in enzymatic PPTs (left)
are higher than that related to
the left-out ones (right).
associations with its cognate whole protein is removed (FDR=0.05); enzymatic PPT whose is not
signicantly associated to its cognate whole protein conditioning on a second enzymatic PPT is
eliminated (FDR = 0:05, Section 3.3.5.1, Figure 3.53).  3500 enzymatic PPT passes this ltering.
A simple comparison of hpMIs related to kept-in and left-out enzymatic PPTs, Figure 3.57, shows
that MIs related to kept-in enzymatic PPTs are indeed signicantly higher than that from the
left-out set.
Correlation computation for data with missing values When missing value presents, it
is usually either removed (depletion) or lled in with other value (imputation). However, both
methods are problematic. In a simulation experiment, I rst creates a random dataset following
Gaussian distribution, and randomly set missing values with a prexed missing data proportions
(NA% = 30%, 50%, or 70%, called random dataset X1). Based on this dataset, I then calculated
Spearman Correlation (Rho) based on depletion and imputation (NA-depletion, NA-imputation).
Theoretically, if there is no biased introduced, a perfect correlation between these two methods
shall be expected - that is all correlations should be along the diagonal in Figure 3.58a. However,
clear discrepancy shows up - these two methods are illustrated to poorly correlated. In particular,
when there are high percentage of missing values (Orange points and line in Figure 3.58a), no
correlation is observed between these two methods.
When there is intrinsic association in data, the bias of NA imputation or NA depletion is further
amplied. Herein, I rst created a full matrix with intrinsic correlation by initiating an covariance






















































Figure 3.58: Correlations computed based missing value Imputation or Depletion are biased to missing data
percentage in (a).simulated random data (X1) and (b). simulated data with positive intrinsic correlation
(X2).
with missing values that follow a multi-dimensional binomial distribution that is controlled by the
same covariance matrix, thus generating an intrinsically correlated dataset with missing values
(X2). Similar as for the random dataset X1, both NA-depletion and NA-imputation methods
correctly recapture the range of correlation in the data, [ 1; 1] for randomly simulated data (X1)
and [0; 1] centering around 0.7 for correlated simulated data (X2). When comparing the same NA
percentage, 70% for example, biases of NA-depletion and NA-imputation from X2 are larger than
that X1. (Figure 3.58b).
For both X1 and X2, data with 30% missing values shows the least biases as expected (Green
points in Figure 3.58). However, the bias increases with the percentage of missing values increas-
ing. This degeneration of correlation computation is further exacerbated for X2 comparing to X1.
Besides, correlation based on NA-imputation is in general lower than that on NA-depletion. this
correlation discrepancy is further exaggerated when more missing values present. Probably impu-
tation based on Gaussian model introduces noise to the original data, thus overwhelms the original
association residing in the non-missing values. When more missing values present, calculation of
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association is more severely confounded by the way to treat the missing values in computation.
Herein, depletion removes information, whereas imputation adds information, thus both of them
are not totally authentic to the data, leading to inaccurate inference of associations.
Mutual Information computation for data with missing values Noted of these limitations,
I devised hybrid-partition MI (hpMI) that calculates MI while keeping the missing values where
they are, without imputation and depleting, and direct handles them in algorithmic computation.
The new schema retains the original information in data in the best possible way (Section 3.3.5.2,
Figure 3.58b). Using the previously simulated random dataset (X1), hpMI successfully recovers the
associations between MI and Correlation - most pairs centering around zero having small MI, and
high correlated pairs, both positive and negative, having high MIs. This trend is highligted by the
red tting line in Figure 3.59a right plot that has a concave shape dened by correlation and MI.
On contrary, MIs based on imputation and depletion fail to capture the relationship: most pairs
sit down with small MI regardless of the correlation (Figure 3.59a left, middle plot).
Likewise, similar computation using the simulated correlated dataset (X2) reveals a even clearer
pattern between hpMI and correlation for each pair (Figure 3.59b right plot). With a center at 0.7,
the higher correlation goes, the bigger hpMI goes, indicated by the regression line colorred in red.
On the contrary, neither imputation or depletion highlights this consistency, or recovers higher MI
for the pairs with high associations (Figure 3.59a left, middle plot).
In summary, these in silico experiments shows hpMI, the a critical component of hpARACNE,
is capable of recovering the association for data of various sparsity without modifying information
in original data.
Next, I checked hpMI perform on real data, the CPTAC phosphoproteomics data. I rst ran-
domly selected phosphopeptides with  50% values from the dataset, then computed the same
metrics, correlations based on NA-imputation and NA-depletion, MI and hpMI. An explicit non-
linear association between hpMI and correlation shows up: higher MIs are associated with either
stronger correlations with a concave curve indicating that there are highly associated pairs in the
data (Figure 3.60a right, red curve). Instead, neither imputation or depletion reveals this clear-cut
association (Figure 3.60a left and middle plot).
Without pre-setting maximum missing value percentage, using all CPTAC proteomics data to
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Figure 3.59: Comparison of Correlation and MI based on Imputation (left), Depletion (middle) and Hybrid-
partition using (a). simulated random data (X1) and (b). simulated data with positive intrinsic correlation
(Rho= 0:7, X2). Each point in scatter plot is on pair. X-axis is the correlation, Y-axis is the MI. Red line is
the regression line from locally weighted scatterplot smoothing (lowess) using all data points on each plot,
respectively.
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compute correlations and MIs. In general, the clear-cut nonlinear association between correlation
and MIs is obscured. But it re-appears when each point is colored by the percentage of missing
data the pair shares. The pairs with maximal missing value presented have minimal hpMI (Figure
3.60b right plot, blue points). hpMI is high for data pairs with minimal missing values (Figure 3.60
right plot, red points). Thus, when quantications are mostly lost and information is inadequate,
association should be weak, reected by minimal hpMI, but not reected by correlation or MI based
on NA-imputation or NA-depletion.
Interestingly, when impute values, the additional information does not help the association
calculation, but instead depreciates the MI. Figure 3.60 left column illustrates this eect - there
is a large proportion of small MIs. Probably, imputation introduces noise, or imputation is based
on a dierent model from which the data is generated from, thus confounding original signal.
When deplete missing values, the removing of specic datapoints ends up with occasional higher
MIs comparing to imputation, exemplied by the MI computed from pairs with over 70% missing
values (Figure 3.60b middle column, blue points). However, as of reduced data points in calculation,
the variance for MI/correlation is the highest among the three MIs.
3.4.2 Reconstruction of CPTAC breast cancer network using hpARACNE
hpARACNE infers a breast cancer specic signalling network using CPTAC breast cancer dataset
[Zhang et al., 2014; Mertins et al., 2016]. Specically, it uses both phosphoproteomics and global
whole proteomics proles in hpARACNE renement step. Then phosphoproteomics data were used
for hpMI computation and network construction. In the nal network, all phosphopeptides that
were annotated as kinases or phosphatases were used as regulatory phosphapeptides catalyzing
substrates phosphopeptides. After casting to protein names, the nal signaling network includes
278 kinases phosphorylating 5217 substrates, 82 phosphatase dephosphorylating 4532 substrates,
respectively, constituting a network of 168; 260 edges.
To understand dierent types of interactions in the signaling network, fours subnetworks based
on the types of nodes participating for each edge are highlighted: kinase centric (kinase); phos-
phatase centric (phosphatase); kinase-kinase (KK); phosphatase-phosphatase (PP); kinase-phosphatase
(KP). Comparing with the kinase centric subnetwork, phosphatase centric subnetwork is less spe-


















































































































Figure 3.60: The nonlinear association between corrleation (x-axis) and MI (y-axis) in CPTAC data , a
dataset with missing values. MIs are calculated by Imputation (left), Depletion (right) and hybrid-partition
(right) using CPTAC breast cancer dataset (a) for peptides with 50% missing value and (b) for all peptides
regardless of missing value percentage. Each point is one pair. The red and blue hue represents shared
missing values percentages for each pair: blue represents pairs with most missing value, red represents pairs
with least missing value.
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subnet ( 22) (Figure 3.61a). Further sub-selecting kinase-centered network reveals a even more
densely connected subnetwork between the kinases (KK network), which has a statistically sig-
nicant higher degree centrality (0.61) comparing to kinase centric network ( 0.44, one tailed
Kolmogorov-Smirnov (KS) test, p-value= 5:94 12). Suggesting that , if randomly taking same
number of nodes from each network, there are twice edges in the KK network than in the kinase-
centric one (Figure 3.61a left box, 3.61b rst box).
this KK subnetwork is extremely densely connected even when comparing to the other 4 types
of sub-network: phosphatase centric, KP, PP, or randomly selected subnetwork (Random). Such
densely connected sub-network has many functional advantages. If comparing it to an architecture
with less connections/interactions or at structure, a loose networks is incapable of capturing the
heterogeneity of signaling when responding to diverse environmental stimuli. Also, a lose structure
would be very inecient due to number or complexity of proteins required to accomplish same task.
Thus, coordination of dynamic signaling pathways and buering of uctuations in perturbation
could be achieved only with a massive overhead of interactions connecting most enzymes - the KK
networks herein.
3.4.3 hpARACNE network prediction achieves high performance
The original goal is to use ARACNE to construct a signaling network based on proteomics data.
A quick and easy application would be impute the data using Gaussian noise, and then build
signaling neworks based on this imputated-data. This network is the baseline, or negative control for
hpARACNE network. As both global whole proteomics and phosphoproteomics data are available,
I st used ARACNE to inferred signaling networks based on imputated whole proteomics data
(WPT) and phosphoproteomics data (PPT). To construct ARACNE signalling network, I imputed
proteomics and phosphoproteomics data with random small noise using the previously mentioned
Gaussian distribution with mean and variance estimated from each variable. Then ARACNE was
ran on global proteomics data and phosphoproteomics data to produce signalling networks, WPT
and PPT respectively.
Then, I calculated prediction performance by comparing ARACNE networks (PPT and WPT),
hpARACNE-inferred signalling network (HPNET) to the curated gold standard signaling network
































Figure 3.61: Average degree of hpARACNE subnetworks . (a) shows a signicant higher average degree in
kinase-centric (kinase, red) network than that in phosphatase-centric (phosphatase, blue). (b). shows degree
distribution of kinase-kinase (KK) network, kinase-phosphatase (KP) network, phosphatase-phosphatase
(PP) network and randomly subnetwork. The random subnetwork is chose base on the total number of








Figure 3.62: Comparision among hpARACNE and ARACNE networks. (a). shows the overlapped pro-
teins (network nodes) for hpARACNE network (HPNET), ARACNE whole proteomics network (WPT) and
ARACNE phosphoproteomics network (PPT). (b). shows the overlapping enzymes, kinase and phosphatase
across the three networks.
[Peri et al., 2004]; ii) phosphoELM [Diella et al., 2004]; iii) phosphoSitePlus [Hornbeck et al.,
2012], resulting a network of 7915 edges from 334 enzymes to 3303 substrates. 3906 proteins are
shared across WPT, PPT and HPNET. Among them, 206 are either kinase or phosphatase (Figure
3.62). More proteins (n=5367) are unique to WPT might be a result of more quantied proteins
in whole proteome than phosphoproteome. Interestingly, though HPNET had least unique nodes
(786 unique to HPNET comparing with 5367 to WPT, 2097 unique to PPT, Figure 3.62-a), it
retains more enzymes than the other two network (130 unique to HPNET, comparing with 73 and
13 to WPT and PPT, respectively, Figure 3.62-b). HPNET clearly retains more hubs which those
otherwise lost pairs by missing values imputation or depletion.
The predicted substrates of the shared enzymes (n=206) in each network are used in calculation
precision and recall. However, the GSN should be used with cautious. The GSN curation process
is biased, where the well-known enzymes are better studied thus well-connected in the GSN - a
fact that penalizes predictions of understudied enzymes. Thus, I computed precision and recall by
subselecting hubs conditioning on their reported substrates number in GSN. Using dierent minimal
substrates threshold, a Precision-Recall curve was produced for each network (Figure 3.63). With
same precision, HPNET (red line) achieves at least 3 times recall (15.1%) comparing to WPT and
117
PPT (4.5%, 5.2% respectively, Figure 3.63). PPT predicted substrates overlapped more with
GSN than that of WPT, as phosphoproteins abundance is directly related to enzyme activity, while
whole protein abundance is less relevant to signaling. After integrating information from whole
protein and phosphoprotein, hpNET theorectially should and does increase network prediction
recall, without sacricing precision. Moreover, enzymes with a higher connectivity (smaller points
in Figure 3.63 were predicted to have more substrates overlapped with GSN, indicated by the
increased precision at each line (top smaller points in Figure 3.63), supporting the hypothesis that
data-driven network reconstruction is less biased toward well studied enzymes where knowledge-
based (GSN) network usually does. Thus, hpARACNE provides a valuable resource for generating

































Figure 3.63: Network prediction per-
formance. The precision and re-
call of separate network comparing
with curated Gold Standard Network
(GSN). Each line represents one net-
work. Each point represents one sub
network in which all enzymes have
minimal number of substrates (N, the
color of points, N increases from 1 to
120). For all points, the larger a point
is, the bigger the sub-network is.
3.4.4 hpARACNE infers network with high accuracy validated by SILAC
The GSN helps to assess whether predictions were reported in experiments, but it misses context-
specicity of the network - the biology specic to breast cancer tumor samples whose proles were
used to constructed networks. Breast cancer cell lines are well-known systems to study breast
cancer biology. Herein, I used experimentally identied substrates by Stable Isotope Labeling with
Amino acid in Cell Culture (SILAC), a technology coupling with MS/MS to quantied proteins
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in cell lines. Specically, I investigated substrates of Epidermal Growth Factor Receptor (EGFR)
[Tzouros et al., 2013].
HPNET
Database




(green, [Tzouros et al., 2013])






test of overlapping shown in Fig-
ure 3.64.
The EGFR substrates were detected in a KPL-4 breast cancer cell line that was treated with
EGFR specic inhibitor, erlotinib, for 5, 10, 30, and 60 minutes before harvesting[Tzouros et al.,
2013]. All quantied substrates were compared to a control sample to compute a log ratio of
change between treatment group and control group, for which proteins with < 1:5, as suggested,
were considered as SILAC experimentally identied EGFR substrates.
Together with those reported in GSN, a prediction accuracy was calculated by comparing to
hpARACNE predicted EGFR substrates (Figure 3.66). Specically, 25 of the predicted EGFR sub-
strates are already known to be phosphorylated by EGFR in GSN, 8 of them were also identied
by SILAC experiment including the auto-phosphorylation, \EGFR-CTNND1", \EGFR-ERBB2",
\EGFR-GAB1", \EGFR-GRB7",\EGFR-KRT7", \EGFR-LYN", and \EGFR-MAPK1". In addi-
tion, phosphorylation level for 20 other substrates changed substantially in the SILAC experiment,
a signicant enrichment of predicted substrates (FET p-value = 9:732 7, Odd Ratio (OR) = 2.64
(Figure 3.66). Even though CPTAC data was not generated by Tyrosine phosphorylation enrich-
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Figure 3.66: Network validation using SILAC and curated database. (a) HPNET predicted EGFR substrates
with high (x-axis, hpMI) are identied by SILAC as top inhibited one (y-axis, fold change). Each point is one
EGFR substrates predicted by HPNET and detected by SILAC. (b).hpARACNE predicted EGFR network,
with edges colored by evidence sources: Database (GSN), SILAC or prediction (New). Points on the circle
are EGFR substrates, colored in red if it is also an enzyme, otherwise in skyblue.
ment, hpARACNE is still able to predicted a signicant number of its substrates beneted from
high sample heterogeneity and large sample size. Even with one breast cancer cell line representing
not all the biology in clinical samples, a signicantly higher fraction of predicted substrates are
recaptured, implicating a probabaly even higher prediction accuracy. When checking the types of
downstream substrates for EGFR and SYK, I found that a large proportion of EGFR substrates
are actually kinases themselves, implicating that the possibility of EGFR functioning as an early
activation kinase in signaling cascade pathways.
Despite of bias of breast cancer cell line model and generality of GSN, hpARACNE inferred
EGFR substrates still recaptures a signicant amount of GSN and SILAC substrates, showing
that the conservation of these substrates across multiple breast cancer cell lines types as well
as the robustness of our method. Noted that, the public SILAC experiments were designed for
enrichment of tyrosine kinase (pY), which was only  2% of the global phosphoproteomics data
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taht was used to reconstruct hpARACNE network. It is undeniable that whole phosphoproteome
quantication could not have the same sensitivity to pY proteins that were quantied by pY
enriched experiments. Still, there are many de novo substrates (n=932) predicted by hpARACNE
that were neither reported by GSN or detected in SILAC experiments. On possibility could be that
some signaling specic to heterogeneous tumor samples is lost in cell line culturing system. Also,
experimental technique dierence between Tyrosine kinase specic substrates (SILAC) and global
phosphoproteomics proling (CPTAC) as mentioned above. It could, of course, be false positive
predictions.
On contrary, databases reports only a very small proportion compared to the observed substrates
in SILAC experiment. This shows a tremendous lack of information of substrates for these kinases,
which is well compensated by hpARACNE prediction. It is important to note that the reported
precision for hpARACNE is estimated using the data from SILAC experiment on a single cell
line, which does not necessarily reect the substrates across other breast cancer samples, thus, the
reported accuracy is an underestimated true accuracy rate of hpARACNE. Regardless, hpARACNE
predicts EGFR substrates with a high accuracy.
3.4.5 Integrative analysis of CPTAC breast cancer tumors
As known, Breast invasive carcinoma - breast cancer - has four molecular subtypes based on gene
expression prole: Basal-like, Her2-enriched, Luminal-A and Luminal-B [Chia et al., 2012]. Among
them, Her2-enriched tumor has increased expression of HER2 (ERBB2), thus responding to HER2
treatment very well. CPTAC dataset has 105 breast cancer tumors, including 25 Basal-like/Triple
negative samples (Epidermal growth factor receptor 2 negative (HER2-/ERBB2-), Estrogen Re-
ception negative (ER-) and Progesterone Receptor negative (PR-)), 18 HER2-enriched tumors, 29
Luminal-A and 33 Luminal-B samples. Their transcriptome and matched phosphoproteome proles
are quantied using iTRAQ-MS/MS.
3.4.5.1 ERBB2 expression and activity pattern is consistent between transcriptome
and proteome
ERBB2 is a biomarker and drug-target for HER2+ breast cancer. Whether it is consistently


















Figure 3.67: ERBB2 expression pat-
terns are consistent across mRNA,
whole protein and phosphoprotein
level.
and phosphoprotein were extracted from the same sample and then quantied by RNA-seq and
MS/MS. ERBB2 whole protein and phosphoprotein are consistently over-represented in HER2-
enriched samples, which is categories to have ERBB2 mRNA over-expression. Comparing to HER2-
enriched samples, it is the most under-expressed/under-represented protein in Basal-like tumor
(Student t-test, p-value = 1:08  10 08; 6:92  10 8; 3:95  10 8, Fold Change = 1:97; 1:9; 1:93 for
mRNA, whole protein and phosphoprotein, respectively. Figure 3.67).
ERBB2, as a kinase, triggers a cascade of singaling events through the signaling network, which
further aects cellular transcriptional eects. Herein, I used hpARACNE inferred signaling network
to understand the signaling cascdes, and ARANCE inferred regulatory network to investigate the
downstream transcriptional circuits. When studying these two networks, I used an established net-
work analysis methods, VIPER [Alvarez et al., 2016b], to infer the functional activity of a controller
protein, ERBB2, based on the network targets quantication, i.e mrna expression, phosphoprotein
abundance. This functional activity of ERBB2 represents the enrichment of ERBB2 predicted tar-
gets/substrates quantication in one sample when comparing to the cohort average. The ERBB2
mRNA transcriptional targets were predicted using ARACNE on the gene expression proles of
CPTAC breast cancer sample. ERBB2 signalling substrates were inferred using hpARACNE based
on proteomics data as previously described. ERBB2 functional activity turns out to be consis-
tently the highest in HER2-enriched tumors comparing to the other three subtypes, and is the
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Figure 3.68: VIPER calculated ERBB2 network-activities are consistently high in HER2 subtype.(a) shows
the two networks used by VIPER: ARACNE transcriptional regulatory network and hpARACNE signalling
network. (b) shows ERBB2 viper/functional activities based on mRNA expression and phosphoproteoin
abundance along wither their separately networks are consistently higher in Her2-riched breast cancer sub-
type comparing to Basal-like and Luminal subtypes.
lowest among all enzymes in Basal-like tumors (Figure 3.68b)
While the ERBB2-centric analysis conrms the existing biological function of ERBB2 in this
context, a systematic analysis of all enzymes (kinase and phosphatase) is needed. A total of 145
enzymes ( with a minimal of 6 targets/substrates) are kept for VIPER analysis. Transcriptional
viper activity (mrnaVP) for each enzyme was rst computed using mRNA expresion and ARACNE
regulator network. Signaling viper activity (phospVP) was then calculated using HPNET and
phosphoproteoin abundance. Next, I compared mrnaVP dierence among the molecular subtypes,
for example, Basal-like versus HER2-enriched (Student T-test). The t-statistics for each enzyme
of this test were plotted in Figure 3.69a x-axis. Likewise, I did the same test for phospVP, whose
t-statistics were plotted along y-axis in Figure 3.69a. Overall, mrnaVP is generally signicantly
positively correlated with phospVP for samples of (Pearson's Correlation = 0:31, p-value = 1:49 
10 4, Figure 3.69a). Clearly ERBB2 is the top functional activated kinase among all enzymes
for both mrnaVP and phospVP, implicating that ERBB2 might execute its regulatory functional
straight through kinase phosphorylation activation. Besides, AKT1, NEK4, NEK6, EIF2AK3 and
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RP66KA5 are 5 other HER2-enriched subtype specic activated enzymes, showing a convergence of
signal downstream of ERBB2 pathway. Interestingly, another two kinases, KIAA1804/MAP3K21
and STK25, were discovered as Basal-like subtype-specicly activated kinases. MAP3K21 has been
reported to have negative eect on TLR4 signaling pathway, potentially inhibiting inate immune
reactions [Seit-Nebi et al., 2012].
Triple negative subtype (TNBC) is the most aggressive subtype which is resistant to most
targeted therapy. It is challenging to identify TNBC specic proteins that are drug-able. Kinases
are mostly target-able and could be identied through phosphorproteomics. Transcriptional factors
are critical proteins that regulating critical biological process, i.e. abnormal processes in disease
states. Systematically integrating phosphoproteomics and transcriptional network could help to
reveal those drug-able proteins that responsible for disease state. Herein, to identify TNBC specic
drug-able protein, I did student-t test by comparing mrnaVP/phospVP of TNBC sample with that
of all other samples, including Luminal and Her2-enriched tumors. All enzymes are plotted on
Figure 3.69b), showing a clear positive correlation between mrnaVP and phospVP. Specically, 17
enzymes are consistently dierentially activated for both mrnaVP and phosphoVP, as annotated in
Figure 3.69b. ERBB family proteins, including ERBB2, ERBB3, are consistently de-activated in
Basal-like subtype. MAP3K21 (KIAA1804) kinase is, again, the top activated enzyme in Basal-like
tumors, together with another four enzymes including TTK/MPS1 (Monopolar Spindle 1 Kinase),
LIMK1, PTPN2, and DUPS2.
Specically, MPS1 is reported to be targeted by specic compounds, inhibiting its kinase activ-
ity. Also, it is reported to associate with proliferation by controlling mitosis checkpoint. [Sugimoto
et al., 2017a] has recently discovered a set of compounds that treat a collection of breast cancer cell
lines by inhibiting MPS1. Though it was not aiming at nding the treatment dierence between
Basal-like and Luminal breast cancers cell lines, the reported drug response curve - median IC50
- of those treatments on 15 breast cancer cell lines (8 Basal and 7 Luminal) revealed that MPS1
targeting compounds is specically sensitive to Basal-like cell lines rather luminal cell lines, illus-
trated the signicant smaller IC50 of Basal-like cell line in Table 3.1. Taking all treatment with a
mean IC50 > 10 as non-response, Chi-seq test suggests that all treatments are signicantly sensi-
tive in basal-like cell lines with p-values=4:60 25; 8:18 23; 2:78 24,and 1:59 23 for each compound,
respectively (Table 3.1). Thus, this data suggests that the network-based analysis has provide po-
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Figure 3.69: Basal-like subtype specic kinases/Master Regulators when taking (a).HER2-enrichned samples
as control. (b).Both HER2-enriched and Luminal samples as control. X-axis represents the t-test statistics
when comparing Basal-like samples' mrna-based Viper activity to that of control samples. Y-axis represent
the same measurement but based on phosphoprotein-based Viper activity. Red and blue color hue represents
the sum of X and Y axis values. Hilighted oragned circled genes are those which a maximum P-value of 0.05
for both t-test. The gray line shows a linear regression tting line.
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tential mechanistically explanations for a published work in understanding the treatment dierence
between Basal-like and Luminal breast cancers.
Cell line subtype TNBC subtype Basal Cpd 1 Cpd 1-SE Cpd 2 Cpd 2-SE Cpd 3 Cpd 3-SE Cpd 4 Cpd 4-SE ctrl ctrl-SE
CAL-51 TNBC Basal 0.23 0.04 1.26 0.24 0.3 0.01 0.55 0.1 2.92 1.08
HCC1937 TNBC Basal 0.73 0.25 0.84 0.15 1.1 0.01 1.02 0.07 >10 -
BT-20 TNBC Basal 0.35 0.38 0.06 0.01 1.71 0.21 0.37 0.2 >10 -
BT-549 TNBC Basal 0.81 0.17 2.19 0.59 1.3 0.01 0.06 0.27 1.73 0.71
MDA-MB-436 TNBC Basal 0.9 0.28 5.23 3.94 1.23 1.01 0.66 0.35 >10 -
MDA-MB-468 TNBC Basal 0.19 0.07 1.57 0.29 0.32 0.04 0.35 0.22 1.85 0.51
Hs578T TNBC Basal >10 - >10 - >10 - >10 - >10 -
MDA-MB-231 TNBC Basal >10 - 0.4 0.05 >10 - >10 - >10 -
CAMA-1 No Luminal 0.36 0.02 0.84 0.71 0.65 0.13 0.6 0.47 >10 -
Sk-Br-3 No Luminal >10 - 0.75 0.22 0.47 0.01 0.4 0.38 >10 -
AU565 No Luminal >10 - >10 - >10 - 0.95 0.15 >10 -
T47D No Luminal >10 - 0.33 0.18 >10 2 >10 - >10 -
MDA-MB-453 No Luminal 0.82 0.1 >10 - >10 - 0.35 0.06 >10 -
MCF-7 No Luminal 0.44 0.21 0.35 0.01 0.3 0.09 >10 - >10 -
BT-474 No Luminal >10 - 0.47 0.23 0.29 0.04 0.05 0.01 >10 -
.
Table 3.1: TTKMPS1 targeting compounds are specically sensitive to Basal-like breast cancer cell lines.
Table was adjusted from work done by [Sugimoto et al., 2017b]
3.5 Conclusion and Discussion
In this work, I present a new algorithm hybrid proteomics Accurate Reconstruction of Accurate
Cellular Networks - hpARACNE - to infer kinase/phosphatase signalling network using proteomics
data from Cancer Clinical Proteomics Research Assay Portal (CPTAC). To my knowledge, this
is the rst method to accomplish data-driven signalling network reconstruction based on whole
genome-wide phosphoproteomics and global proteomics data from clinical samples. As one of the
rst in its kind, hpARACNE achieves at least 3 times recall at the same precision when comparing
to ARACNE signalling network constructed using the same but imputed whole proteomics or
phosphoproteomics data. When comparing to experimentally detected interactions, hpARACNE
predicted EGFR and SYK substrates were successfully recaptured in a high accuracy by doing
SILAC experiments on dierent breast cancer cell lines, showing hpARACNE capacity of revealing
biologically meaningful signalling circuits.
Data sparsity/missing data issue have been a challenge in computation. Contrary to conven-
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tional imputation or depletion, the novel strategy of dealing missing value in computing Mutual
Information (MI) in hpARACNE represents an unbiased design and innovative thinking to related
problems. With fast generation of single cell genomics, transcriptomics or even proteomics, the ap-
proaches proposed by hpARACNE would of great value to the computation eld. When interrogat-
ing hpARACNE signalling network to address context-specic biological questions, I demonstrated
its power of prioritizing potential drugs for treating Basal-like breast cancer, the most aggressive
breast cancer subtype. When integrating with transcriptional information, TTK/MSP1 kinases was
discovered as the top drugable kinase as well as Master Regulator who is highly active in basal-
like breast cancer. Coincidentally, drug sensitivity data from previous study by [Sugimoto et al.,
2017b] has shown treatment-response specicity of TTK/MSP1 targeting drugs, as an compelling
experimental evidence for this discovery.
Given the conservative property of most signalling process, the hpARACNE CPTAC breast
cancer signalling network would be of great value to biologists studying other tumors. By asking
specic questions, interrogation of signalling network using methods like GSEA [Subramanian et
al., 2005] and VIPER [Alvarez et al., 2016b] could help understand signalling cascade mechanism
and prioritize potential kinase/phosphatase as drug-able targets, an advantage that genomics or
transcriptomics study usually does not have.
As a derivative of ARACNE, hpARACNE still holds the assumptions as ARACNE does. Thus,
hpARACNE performance was assessed based on improvements of prediction precision and accuracy
by comparing to that of ARACNE constructed networks which is only optimal for transcriptional
regulatory network reconstruction. Thus, one could argue the fairness of this comparison. However,
with previous work [Margolin et al., 2006], I noticed that hpARACNE signalling network based
on proteomics data achieves similar performance as ARACNE did on transcriptional regulatory
network based on mRNA expression, implicating the success of hpARACNE.
Yet, as both phosphoproteomics and matched whole proteomics data of large samples size
were used as input for hpARACNE, there seems to be some diculty of approaching this type
of dataset if one want to directly apply hpARACNE to other cohort. Indeed, the matched whole
proteomics dataset is just a nice auxiliary to reduce noise in quantication which could be either
skipped, or replaced with heuristic criteria such as prior knowledge on whether a peptide is a
motif-containing peptide or how good the quality is for a specic peptide. Thus, without loss of
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generality, hpARACNE framework is readily applicable to any dataset with or without missing
values.
One should be noted that as a data-driven approach to reverse engineering signalling networks,
hpARACNE does not incorporate structural information such as peptide sequence, phosphorylation
motif and phosphorylation binding domain. Thus, a fair comparison of dierent algorithm perfor-
mances is not readily applicable. However, future improvement of hpARACNE could be achieved







Classical ways of doing biology research rely on dissecting each factor and studying them indi-
vidually. With years of knowledge accumulation, building upon all the well studied components
and fast advancing technology, understanding the interactions among those components become
both necessary and critical to understand biology, especially cancer biology. Systems biology pro-
vides not only a set of tools of understand cancer biology, but also a systematic way of thinking:
From as simple as 2 components interaction in understanding the heterogeneity of a tumor by
studying epithelium and stroma compartmental interactions to as complex as 100,000 interactions
in deciphering signaling transduction by reconstructing network between key players (kinase and
phosphatase) and their targets. The work presented here illustrates utilization of information from
dierent layers of modern molecular biology: mRNA expression of transcriptome; global protein
abundance and phosphorylated protein abundance from proteomics.
In understanding PDA intra-tumor heterogeneity, by designing and applying a new algorithm
ADVOCATE, I showed that stroma compartment in PDA is contributing to patient survival dif-
ference in UNC, ICGC and TCGA cohorts by having dierent type of stroma: immune-rich or
ECM-rich. This work shows conving evidence that ADVOCATE is able to improve on previously
established subtype classiers. This work of actual deconvolution versus virtual deconvolution adds
convincing hard evidence that helps the led understand previously described subtypes: Classical,
exocrine, and quasi-mesenchymal in [Collisson et al., 2011a]; Basal-like and classical epithelium and
Activated and Normal stroma in [Mott et al., 2015] work; Progenitor, squamous, immunogenic
and ADEX in [Bailey et al., 2016]. Yet, In constructing signaling network from proteomics data,
I designed hpARACNe by renovating almost every aspect of the widely used algorithm ARACNe,
showing the algorithms capacity of predicting both experimentally validated and de novo substrates
for specic kinase, providing valuable resources for exploring potential kinases as drug targets and
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Figure 4.70: Systems Biology approaches for personalized medicine, illustrated by understand the transcrip-
tomics in PDA, and proteomics level signalling network reconstruction using proteomics data.
understand their mechanism of action.
Discussion
Currently, I studied PDA epithelium and stroma composition using LCM-based expression data
as training to characterize tumor sample heterogeneity, and associated it with patient survival. In
particular, there has been rapid development and interest in single-cell sequencing technologies that
enable expression proling of individual cells from dissociated tumors. These may then be binned
into cell types to provide unique datasets which is suitable to apply ADVOCATE. Also, Figure 4.70.
interaction/association between stroma and epithelium in patient level is implicated. Interaction
between epithelium cell versus stromal cell could help to characterize cell type heterogeneity. The
intuition comes from observations in my deconvolution project that dierent cell types from same
patient seem to be correlated. Intuitively, removing one cell types from a heterogeneous tumor is
going to aect the remaining cells. As shown by [Rhim et al., 2014a], removing stroma from PDA
did help cancer remission but rather support progression. While, another study by [Bayne et al.,
2012] shows that by inhibiting or blocking antigen-specic T cells in PDA environment. Those
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evidences provide implication and signicance of studying compartmental interactions in tumor
microenvironment. Theoretically, if there are N major cell types in one tumor, nodes, supposably,
there could be N2 cell-cell interactions including the autonomous interactions. The interaction
topology and strength could represent intra-tumor heterogeneity. Simply, if a tumor has 3 cells
types , there are at most 6 types of cell-cell interaction: 3 autocrine interaction, respectively; 3
inter-cell interaction between any 2 of them. Assuming that the interactions between them are
critical for tumor heterogeneity and other phenotypes, changing each cell type is going to aect
other tumor cells through this 6 interactions as explained previously.
However, there are still many challenges. Current single-cell approach doesn't always retain
cell spatial information, without directly physical interaction data, it is not obvious to digest
the inferred interactions. Even though in-situ tracing techniques has been applied widely, it is not
straightforward to synthesize with current technology. Also, in current single cell data, the strongest
signal in expression prole might reect cell cycle stage, timing of going through FACS/ow cell,
etc., but not the cell types heterogeneity, thus dilute the cell type interaction signal.
Using interaction between tumor cell types resides in a big theme of using cancer networks to
understand tumor-to-tumor heterogeneity. The cancer networks could be TF-regulating networks,
Kinase-phosphorylating networks, or even multi-scale hierarchical networks representing interac-
tions among cell, organelles and proteins [Hofree et al., 2013; Krogan et al., 2015]. Application
of dierent types of cancer networks in subtyping whole tumors or even individual tumor cells.
[Wang et al., 2016] has shown the changing of glioblastoma subtypes for one patients from ge-
netics point of view, it is plausible to that those genetic alterations being reected on molecular
network level. As dierent tumor subtypes is shown be treated with dierent drugs [Collisson et
al., 2011a]. The integration of this information will help on discovering combination therapy either
sequentially or spontaneously. Combination therapy could also be systematically computationally
predicted by studying molecular networks by deciphering drug targets and their mode of action.
Previous work by [Woo et al., 2015] used interactome to predict targets of known drugs. But the
interactome used in previous studies are far less than complete. Information in signaling protein
level, epigenetics level and transcriptomics level should be integrated to fully uncover signal cascade
after targeted drug treatment. In general, signaling protein interactions are more conserved across
tissue types while transcriptional networks are more context-specic. One of the rational might be
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that an mRNA expression prole is usually a very sensitive downstream measurement of cell state,
extremely sensitive to genetic and environmental context. In contrast, aspects of signaling may
be more upstream, closer to the mechanisms, such as initiating genetic alterations, that lead to
cancer. In between mRNA and signaling protein, epigenetics level regulation, including chromatin,
histone modication, DNA methylation, might be very critical as it transduces extra-nuclei infor-
mation into more long-lasting transcriptional products. Particularly, chromatin regulation or other
non-TF regulatory mechanisms. Thus, each of these three process might contribute in tumor cell
heterogeneity: i) TF combinations forming modules activating dierently in dierent context; ii).
Chromatin accessibility varying with tissue type. ii) Signaling molecules reactivating dierent to
environmental stimulus. Together, mechanistically, cells would have higher order of heterogeneity.
Typically, DNA variants and mutations are assumed to must necessarily be the initiating cause
of tumor evolution. For natural selection to occur requires a pool of biological variation, heterogene-
ity, in some features which is typically assumed to lie in DNA. However, what if in some cases the
important heterogeneity under selection was not DNA mutations at all, but epigenetic variation?
Several studies has associated epigenetics features with cancers. [Hansen et al., 2011] increased
methylation variation in epigenetic domains across dierent cancer types. [Feinberg et al., 2016]
shows the enrichment of mutation in epigenetics regulation related genes in some specic cancer
type. More and more evidence starts to implicate the signicance of epigenetics in pediatric cancers,
prenatal disorder, or developmental disease [Huether et al., 2014]. Intuitively, those disorders have
a lower chance of accumulating enough mutations to cause disorders, thus the causal events have a
higher chance of coming from other sources. Currently, the biggest challenges in epigenetics is the
data quality. The signal-to-noise ratio, in most cases, is low comparing to other data type. Though,
current ATAC-seq [Buenrostro et al., 2015] starts to gain better data, bringing opportunities to
understanding cancer biology from epigenetics level.
Cancer is a heterogeneous disease, a systems with all components interacting with each other.
Understanding dierent levels of interaction in tumor is one of the rst step to tackle cancer
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C.1 Tables for ADVOCATE
C.1.1 ADVOCATE patients characteristics
Age (years) Median IQR Min Max
69 12.5 48 86
AJCC stage 2A 2B 3 4
19 52 1 3
Surgical margins Negative Positive
56 19
Race Asian Black Hispanic Latino Other White White Latino White Non-Hispanic Unknown
1 5 2 2 60 2 1 2
Gender Female Male
37 38
Primary Site Pancreas CBD/Pancreas
74 1
Location Head Head Body Neck Body Body Tail Tail Diuse CBD/Pancreas
57 2 1 4 2 7 1 1
Tumor grade well well to moderate moderate moderate to poor poor
7 5 36 16 11
Histology Solid pattern N Y
67 8
Mucinous features N Y
71 4
Clear cell features N Y
69 6
Micropapillary growth N Y
70 5
Features IPMN N Y
67 8









Length in bp Length category
ERCC-00002 4.18 104 - 105 1061 1000 bp
ERCC-00003 2.97 102 - 103 1023 1000 bp
ERCC-00004 3.88 103 - 104 523 500 bp
ERCC-00009 2.97 102 - 103 984 1000 bp
ERCC-00042 2.67 102 - 103 1023 1000 bp
ERCC-00043 2.67 102 - 103 1023 1000 bp
ERCC-00046 3.58 103 - 104 522 500 bp
ERCC-00060 2.36 102 - 103 523 500 bp
ERCC-00074 4.18 104 - 105 522 500 bp
ERCC-00095 2.08 102 - 103 521 500 bp
ERCC-00108 2.97 102 - 103 1022 1000 bp
ERCC-00111 2.67 102 - 103 994 1000 bp
ERCC-00130 4.48 104 - 105 1059 1000 bp
ERCC-00136 3.28 103 - 104 1033 1000 bp
ERCC-00145 2.97 102 - 103 1042 1000 bp
ERCC-00171 3.58 103 - 104 505 500 bp










EPYC 6.92 Stromal DMBT1 -5.87 Epithelial
MATN3 6.58 Stromal OLFM4 -5.29 Epithelial
IGF1 6.48 Stromal GABRP -5.22 Epithelial
SFRP4 6.39 Stromal REG4 -5.20 Epithelial
SFRP2 6.24 Stromal TM4SF4 -4.81 Epithelial
IGJ 6.23 Stromal MUC5AC -4.72 Epithelial
LOC100294406 6.18 Stromal TFF1 -4.50 Epithelial
SMOC2 6.06 Stromal SPINK1 -4.30 Epithelial
SFRP1 6.01 Stromal TFF2 -4.29 Epithelial
IGLL5 5.99 Stromal TSPAN8 -4.27 Epithelial
COL14A1 5.92 Stromal VSIG1 -4.06 Epithelial
FGF7 5.91 Stromal CYP3A5 -4.06 Epithelial
COL8A1 5.84 Stromal WDR72 -4.05 Epithelial
COMP 5.76 Stromal CEACAM5 -4.04 Epithelial
OMD 5.63 Stromal KLF5 -3.96 Epithelial
PRELP 5.61 Stromal PROM1 -3.96 Epithelial
HMCN1 5.59 Stromal MUC17 -3.95 Epithelial
DCN 5.56 Stromal CDH17 -3.94 Epithelial
LRRC15 5.54 Stromal MUC4 -3.92 Epithelial
SGCD 5.47 Stromal GCNT3 -3.90 Epithelial
Table C.4: Dierentially expressed genes between paired epithelial and stromal LCM samples (Top 20 for


























SFRP4 6.39 Stroma N N Y N N
IGJ 6.23 Stroma N Y N N N
COL8A1 5.84 Stroma Y N N N N
DCN 5.56 Stroma N Y N N N
MFAP5 5.36 Stroma Y N N N N
FBLN1 5.28 Stroma N Y N N N
PDPN 5.24 Stroma Y N N N N
AEBP1 5.12 Stroma N Y N N N
FBN1 5.11 Stroma Y N N N N
GAS7 5.09 Stroma N N N Y N
THY1 4.98 Stroma Y N N N N
CPA3 4.91 Stroma N N Y N N
MFAP4 4.87 Stroma Y N N N N
BGN 4.80 Stroma N Y N N N
TAGLN 4.78 Stroma Y N N N N
MYL9 4.74 Stroma N Y N N N
F13A1 4.73 Stroma N Y N N N
LAMA2 4.71 Stroma N N N N N
FBLN5 4.70 Stroma Y N N N N
WISP1 4.70 Stroma N N Y N N
SPARC 4.68 Stroma Y N N N N
COL15A1 4.66 Stroma N Y N N N
ACTA2 4.64 Stroma Y N N N N
MAP1A 4.59 Stroma N N N Y N
POSTN 4.56 Stroma Y N N N N
MXRA8 4.55 Stroma N N Y N N


























NTM 4.54 Stroma N N N Y N
ENG 4.53 Stroma Y N N N N
IGFBP7 4.47 Stroma Y N N N N
PDGFRB 4.47 Stroma N Y N N N
CYP1B1 4.27 Stroma N N Y N N
FN1 4.26 Stroma N Y N N N
C1S 4.26 Stroma N Y N N N
ADAM12 4.25 Stroma N N N Y N
CALD1 4.22 Stroma Y N N N N
COL4A2 4.20 Stroma Y N N N N
DKK3 4.11 Stroma N Y N N N
LEF1 4.05 Stroma N N Y N N
FCGR2A 3.95 Stroma Y N N N N
EDNRA 3.93 Stroma N N Y N N
VIM 3.91 Stroma Y N N N N
CNTN1 3.88 Stroma N N Y N N
FCGR3A 3.87 Stroma Y N N N N
PDLIM3 3.86 Stroma Y N N N N
LGALS1 3.85 Stroma Y N N N N
MSR1 3.81 Stroma N Y N N N
CST1 3.81 Stroma N N N Y N
MYLK 3.78 Stroma N Y N N N
ZEB1 3.71 Stroma Y N N N N
MYH10 3.64 Stroma Y N N N N
TACSTD2 -2.80 Epithelium Y N N N


























CP -2.83 Epithelium N Y N N
ABCC3 -2.84 Epithelium Y N N N
KLK10 -2.85 Epithelium N Y N N
ITGB4 -2.91 Epithelium Y N N N
ELF3 -2.96 Epithelium Y N N N
NQO1 -2.98 Epithelium Y N N N
CLDN4 -3.02 Epithelium Y N N N
COL17A1 -3.02 Epithelium Y N N N
KRT19 -3.04 Epithelium Y N N N
TPD52 -3.05 Epithelium Y N N N
SLC44A4 -3.07 Epithelium Y N N N
SOX9 -3.14 Epithelium Y N N N
FAM83B -3.21 Epithelium Y N N N
C1orf116 -3.25 Epithelium Y N N N
MUC13 -3.26 Epithelium N N N Y
CLDN18 -3.26 Epithelium Y N N N
OCLN -3.27 Epithelium N Y N N
GDA -3.28 Epithelium Y N N N
CDH1 -3.30 Epithelium Y N N N
MUC6 -3.32 Epithelium Y N N N
CTSE -3.34 Epithelium Y N N N
FLRT3 -3.36 Epithelium N Y N N
SERPINB5 -3.37 Epithelium Y N N N
TMC5 -3.39 Epithelium N Y N N
PIGR -3.40 Epithelium Y N N N


























CEACAM1 -3.53 Epithelium Y N N N
LGALS4 -3.53 Epithelium Y N N N
ATP1B1 -3.53 Epithelium Y N N N
CLDN2 -3.55 Epithelium Y N N N
CEACAM6 -3.62 Epithelium Y N N N
PLS1 -3.63 Epithelium N N Y N
EPCAM -3.68 Epithelium Y N N N
CXADR -3.69 Epithelium Y N N N
MUC5B -3.78 Epithelium N Y N N
AGR2 -3.88 Epithelium Y N N N
CDH17 -3.94 Epithelium Y N N N
MUC17 -3.95 Epithelium N N N Y
PROM1 -3.96 Epithelium Y N N N
CEACAM5 -4.04 Epithelium Y N N N
VSIG1 -4.06 Epithelium Y N N N
TSPAN8 -4.27 Epithelium Y N N N
TFF2 -4.29 Epithelium Y N N N
SPINK1 -4.30 Epithelium Y N N N
TFF1 -4.50 Epithelium Y N N N
MUC5AC -4.72 Epithelium Y N N N
TM4SF4 -4.81 Epithelium N Y N N
REG4 -5.20 Epithelium Y N N N




Abrv. Full name Abrv Full Name
CUMC HNF3A PID HNF3A PATHWAY Integrin A6B1 PID A6B1 A6B4 INTEGRIN PATHWAY
GATA6 ZHANG GATA6 TARGETS UP Syndecan 2 PID SYNDECAN 2 PATHWAY
Ov. Cancer WAMUNYOKOLI OVARIAN CANCER LMP UP Integrin 4 PID INTEGRIN4 PATHWAY
HNF3B PID HNF3B PATHWAY Cell Cycle POSITIVE REGULATION OF CELL CYCLE
Panc. Exocrine ZHOU PANCREATIC EXOCRINE PROGENITOR EMT HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
Hypoxia HALLMARK HYPOXIA
UNC HNF3B PID HNF3B PATHWAY Syndecan 2 PID SYNDECAN 2 PATHWAY
Panc. Exocrine ZHOU PANCREATIC EXOCRINE PROGENITOR Cell Cycle Up POSITIVE REGULATION OF CELL CYCLE
Ov. Cancer WAMUNYOKOLI OVARIAN CANCER LMP UP Integrin 4 PID INTEGRIN4 PATHWAY
Gata6 ZHANG GATA6 TARGETS DN Rb Path EGUCHI CELL CYCLE RB1 TARGETS
Panc. Beta Cell HALLMARK PANCREAS BETA CELLS Mitosis M PHASE OF MITOTIC CELL CYCLE
Ov. Grade 1/2 WAMUNYOKOLI OVARIAN CANCER GRADES 1 2 UP Cell Cycle CELL CYCLE GO 0007049
ICGC GATA6 ZHANG GATA6 TARGETS DN HIF-1 PID HIF1 TFPATHWAY
HNF3B PID HNF3B PATHWAY Integrin 4 PID INTEGRIN4 PATHWAY
Ova. Cancer WAMUNYOKOLI OVARIAN CANCER LMP UP Syndecan 2 PID SYNDECAN 2 PATHWAY
Panc. Beta Cell HALLMARK PANCREAS BETA CELLS Cell Cycle Reg REGULATION OF MITOTIC CELL CYCLE
Panc. Exocrine ZHOU PANCREATIC EXOCRINE PROGENITOR Cell Cycle Up POSITIVE REGULATION OF CELL CYCLE
Ova. Grade 1/2 WAMUNYOKOLI OVARIAN CANCER GRADES 1 2 UP Hypoxia HALLMARK HYPOXIA
TCGA Gata6 ZHANG GATA6 TARGETS DN Rb Path EGUCHI CELL CYCLE RB1 TARGETS
Ova. Cancer WAMUNYOKOLI OVARIAN CANCER LMP UP Cell Cycle Up POSITIVE REGULATION OF CELL CYCLE
Panc. Progenitor ZHOU PANCREATIC EXOCRINE PROGENITOR Integrin 4 PID INTEGRIN4 PATHWAY
Ova. Grade 1/2 WAMUNYOKOLI OVARIAN CANCER GRADES 1 2 UP A6B1 PID A6B1 A6B4 INTEGRIN PATHWAY
HIF1 PID HIF1 TFPATHWAY
EMT HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
Table C.6: Abbreviations for Gene Sets in Heatmap Figures
